1
|
Patt DA, Patel AM, Bhardwaj A, Hudson KE, Christman A, Amondikar N, Escudier SM, Townsend S, Books H, Basch E. Impact of Remote Symptom Monitoring With Electronic Patient-Reported Outcomes on Hospitalization, Survival, and Cost in Community Oncology Practice: The Texas Two-Step Study. JCO Clin Cancer Inform 2023; 7:e2300182. [PMID: 37897263 PMCID: PMC10642897 DOI: 10.1200/cci.23.00182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 09/25/2023] [Accepted: 09/29/2023] [Indexed: 10/30/2023] Open
Abstract
PURPOSE There is raising interest to implement electronic patient-reported outcomes (ePROs) for symptom monitoring to enhance the quality of cancer care. Step 1 of the Texas Two-Step Study demonstrated successful implementation of an ePRO system in >200 sites of service of a large community oncology practice. We now report step 2 of this study which evaluates the impact of ePROs on outcomes among patients enrolled in the Centers for Medicare & Medicaid Services' Oncology Care Model (OCM) program. METHODS This observational study focused on patients with metastatic cancer enrolled in OCM at large community oncology practice located in Texas between July 2020 and December 2020. Patients who completed ≥1 survey via the ePRO tool were included in the study group and were propensity score matched with patients in a control group. Adverse events (AEs; hospitalizations, emergency department visits, deaths) and total cost of care were a priori study outcomes. Mann-Whitney U and chi-square tests compared continuous and categorical variables, respectively, with multivariable logistic regression for adjustment of covariates. RESULTS Of 831 patients with metastatic cancer, 458 matched patients (229/group) were identified, with 52% male and a mean age of 74 years. Mean total AEs were lower in the study group compared with control (0.98 v 1.41; P = .007), with decreased hospitalizations (20% v 32.5%; P = .002), emergency visits (38.4% v 42.3%; P > .05), and deaths (11.8% v 16.6%; P > .05). Average number of hospitalizations was lower (0.28 v 0.52; P = .003) with reduced mean duration of hospitalizations (1.9 vs 3.2 d; P = .03). The total cost of care was reduced by an average of $1,146 per member per month. CONCLUSION Symptom monitoring with ePROs improved quality and value of cancer care delivery by reducing hospitalizations, emergency visits, and deaths while lowering cost of care in a large oncology practice.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Ethan Basch
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| |
Collapse
|
2
|
Hoegger B, Townsend S, Ortega L, Mikan SQ, Patt DA, Books H. Remote triage and the oncology patient experience. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.28_suppl.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
297 Background: Investments in infrastructure to enhance care delivery are often partnered with practice participation in alternative payment model contracts and innovative care delivery models. Oncology nurses routinely are physically located in a cancer practice. We sought to understand the impact of centralizing resources to work remotely building upon triage pathways already in place on staffing and symptom call resolution with the goal of optimizing outpatient symptom management and patient satisfaction. Due to a national RN shortage and a historical high number of RN vacancies in oncology, we thought this this innovative staffing solution may attract, retain, and elevate the role of RNs. Methods: A needs assessment was conducted to evaluate call volumes, staff levels and duties. A gap analysis was performed to determine which duties would be assigned to remote triage versus in person staffing. Some sites had triage; all sites upgraded to new optimization of assessment and management. Standardized evidence based care and communication pathways were implemented. RNs were trained to follow structured workflows for call ticket resolution. A regional pool supported primary triage RNs who were assigned to each site. The model allowed for flexible staffing while building and maintaining relationships with local providers. Additionally, remote triage RNs were given the opportunity to augment their assessment with audio/visual telehealth as needed. Results: In the first 4 months, 9 pilot sites decreased symptom management time by 50%; 1 site decreased by 70% (over 120 minutes down to 27 minutes). Since remote triage began, average resolution times reduced from 2.52 hours to 1.31 hours. One pilot site had an in-person triage position posted and attracted 4 applicants over 4 weeks. When the position was converted to a remote role, 38 applications were received in 1 week. Offering remote triage positions allowed RN recruitment from other states and gave tenured RNs within the organization an attractive new work model. Conclusions: Remote RN work is an attractive opportunity for RNs allowing for broader recruitment of candidates. Removing triage RNs from the clinic site allows them to focus on triage resolution and as a result call resolution times decreased substantially. Standardized communication pathways were developed, rolled out, and optimized in both virtual and in-person Triage RN roles statewide. Adherence to these communication pathways is critical to ensuring timely symptom management resolution and a sustainable workforce.
Collapse
|
3
|
Toth S, Long CL, Townsend S, Mikan SQ, Hoegger B, Patt DA, Books H. APPs provide high-quality specialty care in virtual clinic. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.28_suppl.390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
390 Background: In our team-based approach to care delivery, Advanced Practice Providers (APPs) are a critical component of the care delivery team. In our statewide oncology practice APPs are not available at each site, limiting our ability to provide program visits that enhance patient care and limiting our flexible staffing capacity. APP program visits - Advance Care Planning (ACP), Treatment Review and Coordination (TRC) and Genetics – had limited availability due to the capacity of existing APP staff. We sought to provide both enhancements in patient care with program visits and offer flexible staffing capacity across our statewide practice by using a centralized virtual care clinic model providing high quality specialty care via Telemedicine. Methods: Four APPs were identified and trained to provide full-time telemedicine services statewide under a single collaboration agreement with the Virtual APP Medical Director. Local sites went through a brief onboarding process with the Virtual APP clinic and then submitted requests for appointment coverage by the Virtual APP (VAPP) team. The VAPPs had the same core oncology training, with a few differentiated skills which were matched with coverage requests aligning with their skill sets. To ensure continuity of care, virtual APP clinic notes were visible statewide in the practice EHR, and local providers were alerted by chart message of significant patient concerns. Results: In the first 3 months of service, the VAPPs completed 1,040 appointments for 12 clinics. The VAPPs conducted 50% Program visits and 50% established patient visits (follow-up, on treatment and urgent care). Conducting the Program visits virtually allowed patients to invite family members from any location to join the appointments virtually. The Urgent Care capability was not used frequently in the first 90 days of service, but may still grow in the future. Conclusions: The Virtual APP program ensured oncology patients received high quality, timely care through 1,040 completed visits. This prevented delays in care, resolved staffing challenges, expanded care, and supports virtual care in oncology. This program ensures APPs are available when and where needed and allows them to efficiently serve multiple clinics. The VAPPs provided education, assessment, prevention, and management of toxicities in a flexible manner.
Collapse
|
4
|
Townsend S, Hoegger B, Ortega L, Patt DA, Books H, Mikan SQ. Impact of statewide telemedicine support model in a community oncology practice. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.28_suppl.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
391 Background: While there was broad adoption of telemedicine during the COVID-19 pandemic, optimizing the interaction for patients and the clinical team remained a challenge. We sought to optimize delivery of telemedicine services to provide more efficient and effective patient care. Target areas of concern for improvement were scheduling, staffing, communication, technical challenges with operating the platform, a high cancellation rate, and limited copay collections. Methods: A team of 8 virtual Patient Service Coordinators (VPSCs), 8 virtual Medical Assistants (VMAs), and an RN clinical manager was created to work remotely from home to serve Providers at 8 clinics. VPSCs performed check-in duties, demographics, copay collection and technology trouble-shooting with patients. VMAs performed medical intake (medication reconciliation, depression screenings, and vital signs) with real-time EMR input. VMAs stayed in-touch with patients to communicate Provider delays. Standardized communication pathways connected virtual teams with in-clinic teams. The clinics selected to participate in the TMS program were conducting 29% - 50% of E&M visits by telemedicine. The goal of the TMS program was to reduce stress and burnout, as well as relieve in-clinic staff of telemedicine duties giving them capacity to address in-clinic COVID related staff shortages. Results: The TMS Program supported 15,500 visits (11/15/21 – 5/31/22) and increased upfront expected copay collection from 9% pre-program to 100% post program. The program reduced the time for first contact on video from 18 minutes to 1 minute and reduced the telemedicine cancellation rate by 3%. The supported TM cancellation rate was 7% lower than in-person visit cancellation rate. A geographically distributed work from home team was able to support a 66% increase in visits during inclement weather days which allowed visits to be completed that would have otherwise been canceled due to clinic closures. Additionally, the TMS program relieved workload for in-clinic staff and the VPSC and VMA positions proved highly desirable to the eligible workforce. Conclusions: The TMS Program improved patient connectivity and experience, increased upfront co-pay collection, decreased burden on in-clinic staff, allowed continuity of care during inclement weather, and was an attractive work option for staff. Due to its success, the program moved past pilot phase into an operational program.
Collapse
|
5
|
Patel AM, Bhardwaj A, Basch E, Hudson KE, Escudier SM, Books H, Kaushik B, Pearson B, Bays C, Townsend S, Patt DA. Evaluating mass implementation of digital health solutions to improve quality and reduce disparities in a large multisite community oncology practice. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.1507] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1507 Background: There is a priority to accelerate the delivery of digital health solutions (DHS) to provide patients with enhanced means for accessing care, but lack of understanding of their utility in certain populations. There are concerns that equitable adoption translate into disparities. We sought to implement a portfolio of DHS across a large practice and characterize engagement across populations to enhance clinical informatics solutions that support care delivery. Methods: This is a retrospective evaluation of cancer patients who engaged with a portfolio of DHS between March 1, 2019 and January 15, 2022. We included four tools with opt-in and opt-out functionality: (1) a care management (CM) platform utilized by clinical staff to manage patient activities, (2) an electronic patient-reported outcomes (ePRO) remote monitoring program for tracking symptoms and oral adherence, (3) a patient portal (PP) for securely accessing patient health records, and (4) digital education (DE) for patients regarding disease and treatments. The engaged population was defined as the number of enrolled patients with at least one (1) record of triage activity, (2) completed ePRO assessment, (3) PP login, and (4) DE read activity, for each tool, respectively. The start of the index period was adjusted based on the first go-live date of each tool. We evaluated factors (age, gender, race/ethnicity, preferred-language, marital status, and distance from clinic) associated with patient engagement using Chi-Square test and multivariate logistic regression. Results: This analysis included a total of 267,375 unique patients. Of the enrolled population per tool, 172,840 (73.6%), 9,938 (67.7 %), 49,771 (79.2%), and 12,044 (56.9%) patients were engaged in CM, ePRO, PP and DE, respectively. The majority (>50%) of engaged patients were female, White and non-Hispanic/Latino, English-language, and aged 61-80 yrs. After adjusting for covariates, we observed that White and non-Hispanic/Latino [(CM: OR 1.15, ePRO OR 1.46, PP: OR 1.48, and DE: OR 1.36) and English-language (CM: OR 1.2, ePRO OR 1.67, PP: OR 1.8 and DE: OR 1.89) patients were significantly (p-value <0.001) more engaged compared to their counterparts. Male patients were less likely to be engaged in CM (OR: 0.79) and ePRO (OR: 0.65) but more engaged in PP (OR: 1.1) compared to females. No significant difference was observed in engagement between non-rural (<20 mile) vs. rural (≥ 20 miles) and in all age groups 21-40, 41-60, 61-80 and >80 years as compared to reference age of 0-20 years for any digital tools except CM. Conclusions: DHS can be used to support the cancer patient journey and we demonstrated high utilization in an array of sociodemographic variables in our population. However, tools designed and implemented with different populations in mind to reduce staff burden and lessen the digital divide should be further explored.
Collapse
Affiliation(s)
| | | | - Ethan Basch
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Patt DA, Patel AM, Hudson KE, Escudier SM, Books H, Townsend S, Bhardwaj A, Kaushik B, Pearson B, Bays C, Basch E. Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.1575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1575 Background: Digital health solutions (DHS) allow for enhanced remote communication between patients and clinical staff and the COVID-19 pandemic has brought these tools to the forefront of care delivery. Once adopted, barriers to adequate utilization still exist. Given the important need to decrease digital divides, and the diversity of patients and care settings across our clinic’s 220 sites of service, we sought to understand how utilization of oncology DHS may be limited among certain populations. Methods: We investigated utilization among cancer patients who enrolled and engaged with a portfolio of DHS between March 1, 2019 and January 15, 2022. This portfolio includes three tools: (1) an electronic patient-reported outcomes (ePRO) remote monitoring program for tracking symptoms and oral adherence, (2) a patient portal (PP) for securely accessing patient health records, and (3) digital education (DE) for patients regarding disease and treatments. ePRO completion rate, average number of PP logins, and DE read rate were used as measures of utilization for each tool, respectively, and compared among patients with different age (< 65 and ≥65 years), language preference [English (EL) or Spanish (SL)], and distance from clinic (non-rural: < 20 miles OR rural: ≥20 miles). Mann-Whitney U and Chi-Square tests were used to compare continuous and categorical variables, respectively. Results: This study included a total of 77,347 unique patients representing 651,004 digital encounters. 9,938 patients engaged in ePRO, 49,771 patients in PP, and 12,044 patients in DE. Engagement across all DHS was high in patients of age group < 65 (ePRO: 72.7%, PP: 79.67% and PE 54.7%) as compared to ≥65 years, but the ePRO completion rate is high in ≥65 age group (59.0% vs 55.6%), whereas no significant difference was observed in the PP login activity and DE read rate. EL patients were significantly (p-value < 0.01) more engaged (ePRO 68% vs. 54%, PP: 80% vs. 62%, DE: 57% vs. 37%) and had higher digital utilization (ePRO completion rate: 57.31% vs 53.23%, average PP logins: 7.48 vs 7.14 and DE read rate: 96.2% vs 90.8%) than SL patients across the DHS. Patients living in rural areas comprised roughly 25% of the population and participated across tools similarly as patients living in non-rural areas (ePRO 67% vs. 69%, PP: 79% vs. 79%, DE: 56.9% vs. 56.8%). Utilization of the portfolio was variable based on rural vs non-rural status (ePRO completion rate: 56.3% vs. 57.4%, average PP logins: 7.9 vs. 7.3, DE read rate: 96.02.7% vs 96.3%). Conclusions: Despite variable engagement based on age, language, and rural status across the portfolio, patients within these populations continue to utilize the DHS. How we understand and explore enhancements to DHS remain under investigation for tool optimization for patient-specific barriers to care.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Ethan Basch
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| |
Collapse
|
7
|
Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, Kirshner JJ, Krop IE, Lin NU, Morikawa A, Patt DA, Perlmutter J, Ramakrishna N, Davidson NE. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. J Clin Oncol 2022; 40:2612-2635. [PMID: 35640077 DOI: 10.1200/jco.22.00519] [Citation(s) in RCA: 55] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
PURPOSE To update evidence-based guideline recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. METHODS An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 545 articles. Outcomes of interest included efficacy and safety. RESULTS Of the 545 publications identified and reviewed, 14 were identified to form the evidentiary basis for the guideline recommendations. RECOMMENDATIONS HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab deruxtecan for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations. There is a lack of head-to-head trials; therefore, there is insufficient evidence to recommend one regimen over another. The patient and the clinician should discuss differences in treatment schedule, route, toxicities, etc during the decision-making process. Options include regimens with tucatinib, trastuzumab emtansine, trastuzumab deruxtecan (if either not previously administered), neratinib, lapatinib, chemotherapy, margetuximab, hormonal therapy, and abemaciclib plus trastuzumab plus fulvestrant, and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4-6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor-positive or progesterone receptor-positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone.Additional information is available at www.asco.org/breast-cancer-guidelines.
Collapse
Affiliation(s)
| | | | - Sarah Temin
- American Society of Clinical Oncology, Alexandria, VA
| | | | | | | | | | - Ian E Krop
- Dana-Farber Cancer Institute, Boston, MA
| | | | | | | | | | - Naren Ramakrishna
- University of Florida Health Cancer Center at Orlando Health, Orlando, FL
| | - Nancy E Davidson
- Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
| |
Collapse
|
8
|
Ramakrishna N, Anders CK, Lin NU, Morikawa A, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Franzoi MAB, Kirshner JJ, Krop IE, Patt DA, Perlmutter J, Giordano SH. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. J Clin Oncol 2022; 40:2636-2655. [PMID: 35640075 DOI: 10.1200/jco.22.00520] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
PURPOSE To provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer up to 2021. METHODS An Expert Panel conducted a targeted systematic literature review (for both systemic therapy for non-CNS metastases and for CNS metastases of HER2+ guideline updates) that identified 545 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. RESULTS Of the 545 publications identified and reviewed, six on systemic therapy were identified to form the evidentiary basis for the systemic therapy for CNS metastases guideline recommendations. RECOMMENDATIONS Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Memantine and hippocampal avoidance should be added to whole-brain radiotherapy when possible. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment onto a clinical trial, and/or palliative care. There are insufficient data to recommend for or against performing routine magnetic resonance imaging to screen for brain metastases; clinicians should have a low threshold for magnetic resonance imaging of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer.Additional information is available at www.asco.org/breast-cancer-guidelines.
Collapse
Affiliation(s)
| | | | | | | | - Sarah Temin
- American Society of Clinical Oncology, Alexandria, VA
| | | | | | - Nancy E Davidson
- Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
| | | | | | - Ian E Krop
- Dana-Farber Cancer Institute, Boston, MA
| | | | | | | |
Collapse
|
9
|
Patt DA, Patel A, Wilfong LS, Books H, Ortega L, Franklin M, Croft S, Stover AM, Boren R, Basch EM. Patient and clinician perceptions of a digital patient monitoring program in the community oncology setting: Findings from the Texas Two-Step Study. J Clin Oncol 2021. [DOI: 10.1200/jco.2020.39.28_suppl.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
189 Background: Digital monitoring strategies that include electronic patient reported outcomes (ePRO) measures to monitor symptoms among cancer patients have been shown to be effective in improving patient outcomes in a large academic setting and across several smaller multi-center trials. However, demonstration of clinical utility in the real-world setting must incorporate patient and provider perspectives of ePRO programs to ensure successful implementation. We sought to understand perceptions among patients and clinicians in ePRO digital symptom monitoring program. Methods: Texas Two-Step is an ongoing hybrid implementation-effectiveness study of Navigating Cancer’s ePRO digital monitoring program at Texas Oncology. Patients initiating new systemic therapy for their cancer diagnosis were introduced to the program by their oncologist and enrolled in the program by nursing staff for weekly reporting of symptoms based on a modified version of NCI’s PRO-CTCAE instrument. Feedback surveys were administered to both patients and clinic staff after 6 months of implementation of the program to evaluate the overall experience with the program. Results: 1040 (23.5%) patients and 215 (12.4%) clinicians completed the feedback survey. Of the patient responders, 90% found the program very or somewhat easy for reporting symptoms, 85% moderately-extremely beneficial for having symptoms addressed, and 84% moderately-extremely interested in utilizing the program for future treatments. Of the clinician responders, 73% indicated that that they had a good understanding of the benefit of the program; 70.6% felt confident in their ability to interpret patients’ ePRO responses; 80.3% felt confident in their ability to discuss the program with patients; 71.2% confident in their ability to counsel patients based on ePRO responses; and 55.3% felt the program enhanced communication with patients. Additionally, 59% of clinicians felt the program was beneficial for patients. Conclusions: Patients have a more favorable perception of the benefit of the ePRO program than clinicians. Methods to reduce staff burden and reinforcement of program benefits during training and implementation are imperative to improve clinical utility and will be studied further as the program is optimized. As implementation occurred during the COVID-19 pandemic, this may impact perceptions regarding the tool.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Ethan M. Basch
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| |
Collapse
|
10
|
Affiliation(s)
- Ziad Bakouny
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
| | | |
Collapse
|
11
|
Wilfong LS, Patel A, Ortega L, Boren R, Pearson B, Jensen TL, Books H, Hudson KE, Patt DA. Improvement in incident resolution time with implementation of an electronic patient management solution at a community oncology practice. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.1578] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1578 Background: Value-based care models such as the Oncology Care Model incentivize practices to reduce hospitalizations and emergency department (ED) visits. Texas Oncology found that most ED visits occurred during regular business hours. Prolonged patient call back times were consistently rated poorly on satisfaction surveys and often led to ED visits for symptoms that could be managed in our offices. We partnered with Navigating Cancer (NC) to implement an electronic patient management technology solution. Methods: For each of our 200 locations, call volume was estimated based on clinic volume. We then reallocated or hired dedicated triage nurses and operators. Incoming calls were entered into the NC dashboard by operators as incidents which were routed based on symptom priority following system generated prompts. Incident volumes and resolution times were tracked. We instituted PDSA cycles at all locations with a goal of less than 90-minute resolution of symptom-related incidents Utilizing the electronic dashboard allowed us to continue this initiative during the COVID-19 public health emergency as our staff could work remotely. Nurses were able to document if a potential ED visit was avoided. These data points allowed our practice to establish comprehensive and strategic actions plans for quality improvement. Results: We finalized implementation of the system in February of 2020. Total incidents for 2020 were over 1 million, averaging over 5000 per location. Resolution time for all incidents started at 3.2 hours pre-implementation and improved to 2.2 hours in December of 2020. Resolution times for symptom-related incidents started at 2.3 hours pre-implementation and ended at 1.5 hours in December of 2020 with over 60% resolved under one hour. 8% of symptom-related incidents resulted in definite or probable ED avoidances by nursing assessment. Shortness of breath, vomiting, chills, and weakness were the top symptom types addressed for ED avoidances. Conclusions: An electronic patient management solution with PDSA cycles of quality improvement can markedly reduce call back times, especially for symptom related calls. We believe managing symptoms in a timely fashion will lower ED visits and hospitalizations as well as improve patient satisfaction. We will report on these outcomes once available.[Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | - Terry Lynn Jensen
- Texas Oncology, The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | | | | | | |
Collapse
|
12
|
Patt DA, Liu X, Li B, McRoy L, Layman RM, Brufsky A. Real-world starting dose and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e13021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13021 Background: Palbociclib (PA) has been approved for HR+/HER2–advanced/metastatic breast cancer (mBC) in combination with an aromatase inhibitor (AI) or fulvestrant for more than 6 years. Regardless of the labeled recommended starting dose of 125mg/day, some patients initiate palbociclib at lower doses in routine practice. This study described real-world starting dose, patient characteristics, and effectiveness outcomes of first line PA+ AI for mBC in the US clinical setting. Methods: We conducted a retrospective analysis of Flatiron Health’s nationwide longitudinal electronic health records, which came from over 280 cancer clinics representing more than 2.2 million actively treated cancer patients in the US. Between February 2015 and September 2018, 813 HR+/HER2– mBC women initiated PA+AI as first-line therapy and had ≥ 3 months of potential follow-up. Patients were followed from start of PA+AI to December 2018, death, or last visit, whichever came first. Real-world progression-free survival (rwPFS) was defined as the time from the start of PA+AI to death or disease progression. Real-world tumor response (rwTR) was assessed based on the treating clinician’s assessment of radiologic evidence for change in burden of disease over the course of treatment. Multivariate analyses were performed to adjust for demographic and clinical characteristics. Results: Of 813 eligible patients, 68.3% were white, median age was 65.0 years, and 42.9% had visceral disease (lung and/or liver). Median duration of follow-up was 21.0 months. 805 patients had records of PA starting dose, with 125mg and 75/100mg/day being 86.5% and 13.5%, respectively. Patients who started at 75/100mg/day were more likely to be ≥75 years than those who started at 125mg/day (38.5% vs 17.1%). Other baseline and disease characteristics were generally evenly distributed. Patients who started at 125mg/day had longer median rwPFS (27.8 vs 18.6 months, adjusted HR=0.74, 95%CI=0.52-1.05) and higher rwTR (54.0% vs. 40.4%) than those patients who started 100/75mg/day (adjusted OR=1.76, 95%CI=1.13-2.74). Table presents results in detail. Conclusions: Most patients in this study initiated palbociclib at 125mg/day and dose adjustment was similar regardless of starting dose. These real-world findings may support initiation of palbociclib at a dose of 125mg/day in combination with AI for the first-line treatment of HR+/HER2- mBC. [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | - Adam Brufsky
- NSABP/NRG Oncology, and the UPMC Hillman Cancer Center, Pittsburgh, PA
| |
Collapse
|
13
|
Patt DA, Wilfong LS, Hudson KE, Patel A, Books H, Ortega L, Pearson B, Boren R, Patil S, Olson-Celli K, Basch EM. Implementation of electronic patient-reported outcomes for symptom monitoring in a large multi-site community oncology practice. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.12103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12103 Background: Among patients receiving chemotherapy, symptomatic adverse event monitoring with electronic patient-reported outcomes (ePRO) is associated with improved clinical outcomes, satisfaction, and compliance with therapy. Standard approaches for ePRO implementation are not established warranting evaluation in community cancer practices. Objective: Evaluate implementation of ePRO symptom monitoring across a large multi-site community oncology practice network. Methods: Patients initiating a new systemic therapy at one of 210 practice sites in the Texas Oncology Practice were invited to use in the Navigating Cancer ePRO platform, with rolling implementation from July-December 2020. Participating patients received a weekly prompt by text message or email (patient choice) to self-report common symptoms and well-being via web or smartphone. Severe self-reported symptoms triggered a real-time notification alert to nursing triage to address the symptom. Enrollment and compliance were systematically tracked weekly with evaluation of barriers and facilitators to adoption and sustainability. Results: 4375 patients planning systemic treatment enrolled and participated, with baseline characteristics are shown in Table 1. 73% (1841/2522) of enrolled patients with follow up completed at least one ePRO assessment, and among these individuals, 65% (8762/25061) of all available weekly ePRO assessments were completed. Over a 10-week period, compliance with weekly symptom reporting declined from 72% to 52%. Patients on oral therapy had higher compliance rates overall. Barriers currently being addressed include lack of a second reminder text/email prompt, inconsistent discussion of reported ePROs by clinicians at visits, and COVID-related changes in workflow. Facilitators included patient and staff engagement on the importance of PROs for symptom management. Conclusions: ePROs can be effectively implemented in community oncology practice. Utilization of ePROs is high, but diminishes over time without attention to barriers. Ongoing work to address barriers and optimize compliance are underway.[Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Ethan M. Basch
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| |
Collapse
|
14
|
Patt DA, Wilfong L, Toth S, Broussard S, Kanipe K, Hammonds J, Allen V, Mautner B, Campbell N, Dubey AK, Wu N, Neubauer M, Jones BS, Paulson RS. Telemedicine in Community Cancer Care: How Technology Helps Patients With Cancer Navigate a Pandemic. JCO Oncol Pract 2021; 17:e11-e15. [PMID: 33434450 PMCID: PMC8202122 DOI: 10.1200/op.20.00815] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
COVID-19 places unprecedented demands on the oncology ecosystem. The extensive pressure of managing health care during the pandemic establishes the need for rapid implementation of telemedicine. Across our large statewide practice of 640 practitioners at 221 sites of service, an aggressive multidisciplinary telemedicine strategy was implemented in March by coordinating and training many different parts of our healthcare delivery system. From March to September, telemedicine grew to serve 15%-20% of new patients and 20%-25% of established patients, permitting the practice to implement safety protocols and reduce volumes in clinic while continuing to manage the acute and chronic care needs of our patient population. We surveyed practice leaders, queried for qualitative feedback, and established 76% were satisfied with the platform. The common challenges for patients were the first-time use and technology function, and patients were, in general, grateful and happy to have the option to visit their clinicians on a telemedicine platform. In addition to conducting new and established visits remotely, telemedicine allows risk assessments, avoidance of hospitalization, family education, psychosocial care, and improved pharmacy support. The implementation has limitations including technical complexity; increased burden on patients and staff; and broadband access, particularly in rural communities. For telemedicine to improve as a solution to enhance the longitudinal care of patients with cancer, payment coverage policies need to continue after the pandemic, technologic adoption needs to be easy for patients, and broadband access in rural areas needs to be a policy priority. Further research to optimize the patient and clinician experience is required to continue to make progress.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Nini Wu
- US Oncology, The Woodlands, TX
| | | | | | | |
Collapse
|
15
|
Thomas CA, Hirschorn AM, Tomkins JE, Birch WE, Bosserman LD, Patt DA, Patel DR, Diaz M, Marsland TA, Klix MM, Balaban EP, Blanchard EM, Franklin GE, Seth R, Norden A. New Landscape: Physician Compensation. JCO Oncol Pract 2020; 17:186-189. [PMID: 33351676 DOI: 10.1200/op.20.00788] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Allison M Hirschorn
- American Society of Clinical Oncology, Clinical Affairs Department, Alexandria, VA
| | - Julia E Tomkins
- American Society of Clinical Oncology, Clinical Affairs Department, Alexandria, VA
| | - Walter E Birch
- American Society of Clinical Oncology, Clinical Affairs Department, Alexandria, VA
| | | | | | | | - Michael Diaz
- Florida Cancer Specialists and Research Institute, St. Petersburg, FL
| | | | - Mary M Klix
- Alaska Oncology and Hematology, Anchorage, AK
| | | | | | | | - Rahul Seth
- SUNY Upstate Medical Center, Syracuse, NY
| | | |
Collapse
|
16
|
Pennell NA, Dillmon M, Levit LA, Moushey EA, Alva AS, Blau S, Cannon TL, Dickson NR, Diehn M, Gonen M, Gonzalez MM, Hensold JO, Hinyard LJ, King T, Lindsey SC, Magnuson A, Marron J, McAneny BL, McDonnell TM, Mileham KF, Nasso SF, Nowakowski GS, Oettel KR, Patel MI, Patt DA, Perlmutter J, Pickard TA, Rodriguez G, Rosenberg AR, Russo B, Szczepanek C, Smith CB, Srivastava P, Teplinsky E, Thota R, Traina TA, Zon R, Bourbeau B, Bruinooge SS, Foster S, Grubbs S, Hagerty K, Hurley P, Kamin D, Phillips J, Schenkel C, Schilsky RL, Burris HA. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol 2020; 39:155-169. [PMID: 33290128 DOI: 10.1200/jco.20.02953] [Citation(s) in RCA: 57] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
This report presents the American Society of Clinical Oncology's (ASCO's) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ensure lessons learned from the COVID-19 experience are used to craft a more equitable, accessible, and efficient clinical research system that protects patient safety, ensures scientific integrity, and maintains data quality. The specific goals are: (1) ensure that clinical research is accessible, affordable, and equitable; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulatory burdens on research sites; (4) recruit, retain, and support a well-trained clinical research workforce; and (5) promote appropriate oversight and review of clinical trial conduct and results. Similarly, ASCO also organized its recommendations regarding cancer care delivery around five goals: (1) promote and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide high-quality patient care; (4) recognize and address threats to clinician, provider, and patient well-being; and (5) improve patient access to high-quality cancer care via telemedicine. ASCO will work at all levels to advance the recommendations made in this report.
Collapse
Affiliation(s)
| | | | - Laura A Levit
- American Society of Clinical Oncology, Alexandria, VA
| | | | | | - Sibel Blau
- Northwest Medical Specialties, Seattle, WA
| | | | | | | | - Mithat Gonen
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | - Tari King
- Dana-Farber/Brigham and Women's Cancer Center, Boston, MA
| | | | | | | | | | | | | | | | | | | | | | | | | | - Todd A Pickard
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Barry Russo
- The Center for Cancer and Blood Disorders, Fort Worth, TX
| | | | | | | | | | | | | | - Robin Zon
- Michiana Hematology Oncology, Niles, MI
| | | | | | | | | | | | | | - Deborah Kamin
- American Society of Clinical Oncology, Alexandria, VA
| | | | | | | | | |
Collapse
|
17
|
Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho JL, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, de la Peña L, Xu N, Wongchenko M, Shi Z, Singel SM, Isakoff SJ. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol 2020; 30:1289-1297. [PMID: 31147675 DOI: 10.1093/annonc/mdz177] [Citation(s) in RCA: 88] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND This hypothesis-generating trial evaluated neoadjuvant ipatasertib-paclitaxel for early triple-negative breast cancer (TNBC). PATIENTS AND METHODS In this randomized phase II trial, patients with early TNBC (T ≥ 1.5 cm, N0-2) were randomized 1 : 1 to receive weekly paclitaxel 80 mg/m2 with ipatasertib 400 mg or placebo (days 1-21 every 28 days) for 12 weeks before surgery. Co-primary end points were pathologic complete response (pCR) rate (ypT0/TisN0) in the intention-to-treat (ITT) and immunohistochemistry phosphatase and tensin homolog (PTEN)-low populations. Secondary end points included pCR rate in patients with PIK3CA/AKT1/PTEN-altered tumors and pre-surgery response rates by magnetic resonance imaging (MRI). RESULTS pCR rates with ipatasertib versus placebo were 17% versus 13%, respectively, in the ITT population (N = 151), 16% versus 13% in the immunohistochemistry PTEN-low population (N = 35), and 18% versus 12% in the PIK3CA/AKT1/PTEN-altered subgroup (N = 62). Rates of overall and complete response (CR) by MRI favored ipatasertib in all three populations (CR rate 39% versus 9% in the PIK3CA/AKT1/PTEN-altered subgroup). Ipatasertib was associated with more grade ≥3 adverse events (32% versus 16% with placebo), especially diarrhea (17% versus 1%). Higher cycle 1 day 8 (C1D8) immune score was significantly associated with better response only in placebo-treated patients. All ipatasertib-treated patients with low immune scores and a CR had PIK3CA/AKT1/PTEN-altered tumors. CONCLUSIONS Adding ipatasertib to 12 weeks of paclitaxel for early TNBC did not clinically or statistically significantly increase pCR rate, although overall response rate by MRI was numerically higher with ipatasertib. The antitumor effect of ipatasertib was most pronounced in biomarker-selected patients. Safety was consistent with prior experience of ipatasertib-paclitaxel. A T-cell-rich environment at C1D8 had a stronger association with improved outcomes in paclitaxel-treated patients than seen for baseline tumor-infiltrating lymphocytes. This dependency may be overcome with the addition of AKT inhibition, especially in patients with PIK3CA/AKT1/PTEN-altered tumors. CLINICALTRIALS.GOV NCT02301988.
Collapse
Affiliation(s)
- M Oliveira
- Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona; SOLTI Breast Cancer Research Group, Barcelona.
| | - C Saura
- Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona; SOLTI Breast Cancer Research Group, Barcelona
| | - P Nuciforo
- Molecular Oncology Group, VHIO, Barcelona
| | - I Calvo
- Breast Cancer Unit, Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain
| | - J Andersen
- Medical Oncology and Hematology, Compass Oncology and US Oncology, Portland, USA
| | | | - M Gil Gil
- SOLTI Breast Cancer Research Group, Barcelona; Medical Oncology Service, Institut Català d'Oncologia, L'Hospitalet, Barcelona; Institut d'Investigació Biomédica de Bellvitge (IDIBELL), Barcelona
| | - B Bermejo
- Hospital Clinico Universitario, Valencia, Spain
| | - D A Patt
- Texas Oncology Cancer Center, US Oncology, Austin, USA
| | - E Ciruelos
- SOLTI Breast Cancer Research Group, Barcelona; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
| | | | - N Xu
- Product Development Oncology, Genentech Inc., South San Francisco
| | - M Wongchenko
- Oncology Biomarker Department, Genentech Inc., South San Francisco
| | - Z Shi
- Oncology Biomarker Department, Genentech Inc., South San Francisco
| | - S M Singel
- Product Development Oncology, Genentech Inc., South San Francisco
| | - S J Isakoff
- Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
| |
Collapse
|
18
|
Patt DA, He B, Garey JS, Rowan P, Swartz MD, Linder S, Brooks BD, Neubauer MA. Driving quality improvement: How clinical decision support can facilitate compliance with evidence-based pathways. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.2045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2045 Background: Cancer care is changing rapidly with more detailed understanding of disease and more numerous therapeutic choices. As treatment choice is more complex, mechanisms to improve compliance with evidence based treatment can improve the quality of cancer care. Methods: A retrospective cohort study was conducted from January 2014-May 2016 evaluating the impact of a clinical decision support system (CDSS) on compliance with evidence based pathways (EBP) across 9 statewide community based oncology practices. These EBP are developed with physician input on efficacy toxicity and value and incorporated in to a CDSS that is used within the Electronic Health Record (EHR) at point of care to alter the choice architecture a clinician sees when prescribing therapy. A multi-level logistic regression model was used to adjust for group effects on physician or practice behavior. SAS 9.4 software was used and GLIMMIX was applied. Individual physician benchmark compliance was evaluated using McNemar's test. Results: Regimen compliance with EBP was measured pre- and post- implementation of the CDSS tool across a large network encompassing 9 statewide practices and 633 physicians who prescribed over 30,000 individual patient treatment regimens over a 6 month period. The CDSS that is incorporated within the EHR significantly improved compliance with EBP across the entire cohort of practices, and in individual practices (see Table). Individual oncologists reached a target of 75% compliance more often (58% vs 72%) after implementation of the tool (p < 0.001). Conclusions: CDSS is a tool that improves compliance with EBP that is effective at improving targets of compliance broadly, at the practice, and at the individual clinician level. Clinical informatics solutions that influence physician behavior can be inclusive of physicians in design, iterative in process, and nudge as opposed to force clinician behavior to drive quality improvement. These clinical informatics solutions grow in importance as the complexity of cancer care continues to increase and we seek to improve upon the quality and value of care delivery. [Table: see text]
Collapse
Affiliation(s)
- Debra A. Patt
- McKesson Specialty Health and US Oncology Network, The Woodlands, TX
| | - Bo He
- McKesson Specialty Health, The Woodlands, TX
| | | | - Paul Rowan
- University of Texas School of Public Health, Houston, TX
| | | | - Stephen Linder
- University of Texas School of Public Health, Houston, TX
| | | | | |
Collapse
|
19
|
Tolaney SM, Kalinsky K, Kaklamani VG, D'Adamo DR, Aktan G, Tsai ML, O'Regan R, Kaufman PA, Wilks S, Andreopoulou E, Patt DA, Yuan Y, Wang G, Xing D, Kleynerman E, Karantza V, Diab S. A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.1015] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1015 Background: As monotherapies, both ERI (a chemotherapeutic microtubule inhibitor) and PEMBRO (a programmed death [PD]-1 blocking immunotherapy) have shown promising antitumor activity in mTNBC. Emerging data suggest that the addition of immunotherapy to traditional chemotherapy holds promise for mTNBC. This open-label, single-arm, phase 1b/2 study evaluated the safety and efficacy of ERI + PEMBRO in mTNBC. Methods: Patients (pts) with mTNBC and ≤2 prior systemic anticancer therapies for metastatic disease were enrolled and stratified by prior number of therapy (Stratum 1, 0; Stratum 2, 1–2). Pts received IV ERI 1.4 mg/m2 on day (d)1 and d8 and IV PEMBRO 200 mg on d1 of a 21-d cycle. The primary objectives were safety and objective response rate (ORR per RECIST 1.1 by independent imaging review). Assessments also included efficacy outcomes by PD ligand-1 (PD-L1) expression status; PD-L1+ was defined as a combined positive score ≥1 using the PD-L1 IHC 22C3 pharmDx. Results: As of data cutoff (July 31, 2019), 167 pts (Stratum 1, n=66; Stratum 2, n=101) were enrolled and treated. No dose-limiting toxicities were observed. The most common treatment-emergent adverse events were fatigue (66%), nausea (57%), peripheral sensory neuropathy (41%), alopecia (40%), and constipation (37%). No deaths were considered treatment related. The overall ORR was 23.4% (95% CI: 17.2–30.5). Efficacy outcomes by PD-L1 status (PD-L1+, n=74; PD-L1-, n=75) and stratum are presented (table). Conclusions: ERI + PEMBRO has activity in pts with mTNBC. There was a trend toward more robust activity for the combination among patients with PD-L1+ tumors compared to PD-L1- tumors in the first-line setting (Stratum 1); whereas, in the later-line setting (Stratum 2) similar survival outcomes were observed among the PD-L1+ and PD-L1- pts. ERI + PEMBRO shows promise for mTNBC with efficacy that appears greater than historical reports of either agent alone. Clinical trial information: NCT02513472 . [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | - Ruth O'Regan
- University of Wisconsin Carbone Cancer Center, Madison, WI
| | - Peter A. Kaufman
- University of Vermont Medical Center, the UVM Cancer Center, and the Larner College of Medicine at the University of Vermont, Burlington, VT
| | - Sharon Wilks
- Texas Oncology-San Antonio Northeast, US Oncology, San Antonio, TX
| | | | | | - Yuan Yuan
- City of Hope National Medical Center, Duarte, CA
| | - Grace Wang
- Miami Cancer Institute-Baptist Health South Florida, Miami, FL
| | | | | | | | - Sami Diab
- Rocky Mountain Cancer Center-Aurora, Aurora, CO
| |
Collapse
|
20
|
Ginsburg A, Wilfong LS, Denduluri N, Howell J, Dickens A, Casey KL, Hsieh A, Burke JM, Cowey CL, Hoverman JR, Knowles LM, Konduri K, Larson T, Paulson AS, Schnadig ID, Andorsky DJ, Neubauer MA, Patt DA. Clinical decision support tools (CDST) provide education at the point-of-care to assist provider treatment choices. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e19165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19165 Background: Cancer care is complex and requires synthesis of increasing amounts of clinical and financial data to optimize treatment decisions. The heightened differentiation of individual cancers, therapy sequencing, and increasing number of treatment options make it more challenging for oncologists to stay current. A survey showed that 82% of Network providers validated the utility of clinical evidence and decision-making assistance at the point-of-care. Providing education on efficacy, toxicity, and cost in the form of evidence tables (ET) as CDST may assist in value-based decision-making. Methods: We retrospectively reviewed utilization of ET developed to provide clinical and financial data about regimens included within the Value Pathways powered by NCCN. Thirty ET were embedded in the electronic health record (EHR) and posted on our intranet between June-December 2019, covering over 90% of cancers. Utilization was queried from roll out through January 2020. ET include a summary of primary literature (primary/secondary endpoints, adverse events) and monthly Medicare allowable reimbursement rates. ET are updated with each change to pathways and quarterly for cost updates. We also conducted a survey to understand provider ET utilization patterns. Results: Utilization was evaluated for 1,200 physicians across 470 sites that have access to ET. ET have been accessed 1178 times by 586 providers within the EHR and accessed 1363 times by 260 providers via intranet. Our rate of repeat users of the ET is 35% in the EHR and 97% on the intranet. A survey of 200 physicians after ET release showed that 19% of physicians use ET with every new chemotherapy start and an additional 50% refer to ET only if they are uncertain about the best option. Conclusions: Utilization patterns underscore the importance of ET as a CDST within the EHR and on the intranet. While early ET use is high, continued tracking of utilization and addition of content to assist in complex clinical decisions is a priority. Providers surveyed found that clinical informatics tools like ET are useful to enhance decision-making in complex cancer care. [Table: see text]
Collapse
Affiliation(s)
- Aimee Ginsburg
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | | | | | - Josh Howell
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | - Andrea Dickens
- The US Oncology Network/McKesson Specialty Health, Houston, TX
| | - Kelly Leigh Casey
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | - Angela Hsieh
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | - John M. Burke
- Rocky Mountain Cancer Centers/The US Oncology Network, Aurora, CO
| | | | | | | | | | - Tim Larson
- Minnesota Oncology/The US Oncology Network, Minneapolis, MN
| | | | | | | | | | - Debra A. Patt
- McKesson Specialty Health and US Oncology Network, The Woodlands, TX
| |
Collapse
|
21
|
Wongchenko MJ, Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos Coelho JI, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, Singel SM, Maslyar DJ, Xu N, de la Peña L, Baselga J, Gendreau S, Isakoff SJ. Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The oral AKT inhibitor IPAT is being evaluated in cancers with a high prevalence of PI3K/AKT pathway activation. In the PBO-controlled randomized phase II FAIRLANE trial (NCT02301988), adding IPAT to PAC as neoadjuvant therapy for TNBC led to a numerical increase in pathologic complete response (pCR) in unselected patients (17.1% vs 13.3%), with a greater treatment effect in patients with PIK3CA/AKT1/PTEN-altered tumors (17.9% vs 11.8%). The addition of IPAT also led to an increase in complete response (CR) by MRI (27.6% vs 13.3%) that was enhanced in patients with PIK3CA/AKT1/PTEN-altered tumors (39.3% vs 8.8%) [Oliveira, AACR 2018]. We report an exploratory analysis performed to provide better understanding of potential biomarkers for response.
Methods: Pretreatment tumor samples were evaluated for genomic alterations using the FoundationOne® (Foundation Medicine) assay (n=144) and gene expression by RNA-Seq (n=92). Samples were classified into TNBC subtypes based on the method developed by Lehmann and Pietenpol [Lehmann, J Clin Invest 2011]. Tumor-infiltrating lymphocytes (TILs) were quantified using the Salgado method [Salgado, Ann Oncol 2015] (n=135).
Results: Of 62 patients (43%) with PIK3CA/AKT1/PTEN-altered tumors, 21 had an activating mutation in PIK3CA or AKT1 and 47 had an alteration in PTEN (6 [3 in each arm] had both PIK3CA mutation and PTEN alteration). Although only 3 patients with PIK3CA/AKT1-mutant tumors achieved a pCR, there was an increased rate of MRI CR with the addition of IPAT to PAC [Table]. In patients with PTEN alterations, both pCR rate and MRI CR rate were increased with IPAT. In patients treated with PBO + PAC, all 4 pCR patients evaluable by RNA-Seq were of the immunomodulatory (IM) subtype. However, in the IPAT + PAC arm, pCRs were also seen in patients with basal-like 1 (BL-1), mesenchymal (M), and mesenchymal stem-like (MSL) subtypes. Consistent with this observation, in the PBO + PAC arm, samples from patients achieving a pCR had significantly higher levels of stromal TILs than those from patients who did not have a pCR, while no difference was observed in the IPAT + PAC arm.
Response, n (%)PIK3CA/AKT mutation (n=21)PTEN alteration (n=47) IPAT + PAC (n=11)PBO + PAC (n=10)IPAT + PAC (n=21)PBO + PAC (n=26)pCR1 (9%)2 (20%)4 (19%)3 (12%)CR by MRI5 (45%)1 (10%)8 (38%)2 (8%)
Conclusions: This retrospective exploratory biomarker analysis of the phase II FAIRLANE trial of neoadjuvant IPAT for TNBC provides insight into the potential heterogeneity of response and resistance to taxane therapy. The results also hint that response to PAC alone is dependent on baseline immune infiltration and that this dependency might be relieved with the addition of AKT inhibition.
Citation Format: Wongchenko MJ, Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos Coelho JI, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, Singel SM, Maslyar DJ, Xu N, de la Peña L, Baselga J, Gendreau S, Isakoff SJ. Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-19.
Collapse
Affiliation(s)
- MJ Wongchenko
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - M Oliveira
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - C Saura
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - P Nuciforo
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - I Calvo
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - J Andersen
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - JI Passos Coelho
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - M Gil Gil
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - B Bermejo
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - DA Patt
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - E Ciruelos
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - SM Singel
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - DJ Maslyar
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - N Xu
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - L de la Peña
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - J Baselga
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - S Gendreau
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| | - SJ Isakoff
- Genentech Inc, South San Francisco, CA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain; Compass Oncology and US Oncology, Portland, OR; Hospital Beatriz Angelo, Loures, Portugal; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Texas Oncology Cancer Center, US Oncology, Austin, TX; University Hospital 12 de October and SOLTI Breast Cancer Research Group, Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
22
|
Parikh RB, Gdowski A, Patt DA, Hertler A, Mermel C, Bekelman JE. Using Big Data and Predictive Analytics to Determine Patient Risk in Oncology. Am Soc Clin Oncol Educ Book 2019; 39:e53-e58. [PMID: 31099672 DOI: 10.1200/edbk_238891] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Big data and predictive analytics have immense potential to improve risk stratification, particularly in data-rich fields like oncology. This article reviews the literature published on use cases and challenges in applying predictive analytics to improve risk stratification in oncology. We characterized evidence-based use cases of predictive analytics in oncology into three distinct fields: (1) population health management, (2) radiomics, and (3) pathology. We then highlight promising future use cases of predictive analytics in clinical decision support and genomic risk stratification. We conclude by describing challenges in the future applications of big data in oncology, namely (1) difficulties in acquisition of comprehensive data and endpoints, (2) the lack of prospective validation of predictive tools, and (3) the risk of automating bias in observational datasets. If such challenges can be overcome, computational techniques for clinical risk stratification will in short order improve clinical risk stratification for patients with cancer.
Collapse
Affiliation(s)
- Ravi B Parikh
- 1 Penn Center for Cancer Care Innovation at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
- 2 Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA
| | - Andrew Gdowski
- 3 Dell Medical School at The University of Texas at Austin, Austin, TX
| | - Debra A Patt
- 3 Dell Medical School at The University of Texas at Austin, Austin, TX
- 4 Texas Oncology, Dallas, TX
| | | | | | - Justin E Bekelman
- 1 Penn Center for Cancer Care Innovation at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
- 2 Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
23
|
Patt DA. Understanding Utilization Management Policy: How to Manage This Increasingly Complex Environment in Collaboration and With Better Data. Am Soc Clin Oncol Educ Book 2018; 38:135-138. [PMID: 30231339 DOI: 10.1200/edbk_200891] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
As innovation in cancer care continues and newer costly therapies receive approval, utilization management will continue to grow as an important way that payers can attempt to control costs and value while providing service to their patients. Although utilization management may be necessary, it takes many forms and is optimized when it ensures appropriate patient access to services and minimizes administrative burdens of physicians and staff. These opportunities are best explored in collaboration with payers. Information systems today provide an excellent platform for data sharing to facilitate collaborative efforts between care delivery organizations and payers to optimize these efforts. As state and national policies differ regarding utilization management, it is important for clinicians to be both aware and involved.
Collapse
Affiliation(s)
- Debra A Patt
- From the McKesson Specialty Health/US Oncology Network, Austin, TX
| |
Collapse
|
24
|
Wilfong LS, Portnoy C, Hoverman JR, Wallace K, Schwartz JR, Dave N, Mikan SQ, Patt DA. Enhanced compliance with appropriate antiemetic prescribing guidelines by utilizing a medically integrated pharmacy antiemetic therapeutic interchange protocol. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.30_suppl.55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
55 Background: Appropriate antiemetic prescribing remains an unmet need in patients receiving emetogenic chemotherapy. Non-compliance with standard antiemetic guidelines is well reported, and a focus of the American Society of Clinical Oncology Choosing Wisely campaign. Using our medically integrated pharmacies, a community oncology practice sought to maximize compliance with national guidelines by minimizing the use of NK1 inhibitors for low and minimally emetogenic regimens and optimizing medications for highly emetogenic regimens per NCCN guidelines. Methods: A retrospective review of a medically integrated pharmacy antiemetic therapeutic interchange policy. Trained oncology pharmacists imbedded within 2 cancer centers evaluated all new chemotherapy orders to determine the level of emetogenicity per NCCN guidelines. Pharmacists then used a guideline compliant prespecified therapeutic interchange protocol to adjust the antiemetic medications. Patient education to enhance medication compliance was performed by the pharmacists, nurses, and in one on one treatment review sessions with an advance practice provider. Results: Of 271 low to minimally emetogenic regimens, 99% did not receive an NK1 inhibitor on the first cycle. Of 367 highly emetogenic regimens, 97% appropriately received guideline based therapy. Additionally, the use of olanzapine was non-existent in the practice prior to this protocol and increased to 55% of patients with highly emetogenic regimens. Conclusions: We demonstrated that a therapeutic interchange policy with a medically integrated pharmacist shows enhanced compliance with guideline based antiemetic medication usage. This system also allows rapid uptake of changes in supportive care guidelines such as rapid adoption of olanzapine. Efficacy results of this protocol will be reported separately.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Debra A. Patt
- McKesson Specialty Health/US Oncology Network, The Woodlands, TX
| |
Collapse
|
25
|
Wilfong LS, Patt DA, Wallace K, Mikan SQ, Portnoy C, Kipley L, Dave N, Schwartz JR, Hoverman JR. Efficacy of an antiemetic therapeutic interchange protocol driven by a medically integrated pharmacy. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.30_suppl.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
133 Background: Control of chemotherapy induced nausea and vomiting (CINV) remains an unmet need. An antiemetic therapeutic interchange protocol was developed to enhance control of CINV. This abstract reports the efficacy results of patients treated with highly emetogenic regimens as defined by NCCN guidelines. Methods: Medically integrated pharmacists imbedded within 2 centers of a community oncology practice evaluated each new chemotherapy order and adjusted antiemetics including a 5HT3 antagonist, steroids, olanzapine and an NK1 inhibitor using an NCCN based protocol. Exact medications depended on insurance coverage and copays. Medications were adjusted for patient comorbidities, drug interactions and patient refusal. All patients were given prochlorperazine and ondansetron for breakthrough nausea and vomiting. Medication education to increase adherence was provided by the pharmacist, nurse and advance practice provider. Patients were evaluated by nursing or pharmacist calls on day 2 and 3 and as needed to characterize CINV using the Multinational Association of Supportive Care in Cancer (MASCC) antiemesis tool that scores CINV on a Likert scale. Based on review of the literature, a score of 3 or higher reflected symptom management failure. Additionally, due to drowsiness as the most commonly reported side effect of olanzapine, each center sought to characterize the risk of drowsiness. Results: 367 consecutive patients treated with highly emetogenic chemotherapy regimens were identified at two centers by pharmacists and followed by nursing or pharmacy calls over a 9-month timeframe: November 2016 to August 2017. 89% of patients had complete control of nausea with only 11% reporting nausea greater than a 3. Additionally, 11% of patients reported drowsiness greater than a 3. Conclusions: Administering a pharmacist driven antiemetic protocol is an effective way to control CINV. While CINV did occur, evaluation shows CINV was mild. We have shown that utilizing an antiemetic therapeutic interchange protocol with a collaborative care team including medically integrated pharmacists facilitates excellent control of CINV.
Collapse
Affiliation(s)
| | - Debra A. Patt
- McKesson Specialty Health/US Oncology Network, The Woodlands, TX
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, Levinson J, Modi S, Patt DA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018; 36:2804-2807. [DOI: 10.1200/jco.2018.79.2713] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To update the formal expert consensus-based guideline recommendations for practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2–positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. In 2014, the American Society of Clinical Oncology (ASCO) convened a panel of medical oncology, radiation oncology, guideline implementation, and advocacy experts, and conducted a systematic review of the literature. When that failed to yield sufficiently strong quality evidence, the Expert Panel undertook a formal expert consensus–based process to produce these recommendations. ASCO used a modified Delphi process. The panel members drafted recommendations, and a group of other experts joined them for two rounds of formal ratings of the recommendations. Results Of the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations. Recommendations Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment in a clinical trial, and/or palliative care. Clinicians should not perform routine magnetic resonance imaging to screen for brain metastases, but rather should have a low threshold for magnetic resonance imaging of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer. Additional information is available at www.asco.org/breast-cancer-guidelines .
Collapse
Affiliation(s)
- Naren Ramakrishna
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Sarah Temin
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Sarat Chandarlapaty
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Jennie R. Crews
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Nancy E. Davidson
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Francisco J. Esteva
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Sharon H. Giordano
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Jeffrey J. Kirshner
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Ian E. Krop
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Jennifer Levinson
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Shanu Modi
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Debra A. Patt
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Jane Perlmutter
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Eric P. Winer
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| | - Nancy U. Lin
- Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy
| |
Collapse
|
27
|
Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018; 36:2736-2740. [DOI: 10.1200/jco.2018.79.2697] [Citation(s) in RCA: 112] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. Results Of the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations. Recommendations HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab emtansine for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4 to 6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor–positive/progesterone receptor–positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone. Additional information is available at www.asco.org/breast-cancer-guidelines .
Collapse
Affiliation(s)
- Sharon H. Giordano
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Sarah Temin
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Sarat Chandarlapaty
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Jennie R. Crews
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Francisco J. Esteva
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Jeffrey J. Kirshner
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Ian E. Krop
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Jennifer Levinson
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Nancy U. Lin
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Shanu Modi
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Debra A. Patt
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Jane Perlmutter
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Naren Ramakrishna
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Eric P. Winer
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| | - Nancy E. Davidson
- Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer
| |
Collapse
|
28
|
Abstract
Objective:
To summarize significant research contributions on cancer informatics published in 2017.
Methods:
An extensive search using PubMed/Medline, Google Scholar, and manual review was conducted to identify the scientific contributions published in 2017 that address topics in cancer informatics. The selection process comprised three steps: (i) 15 candidate best papers were first selected by the two section editors, (ii) external reviewers from internationally renowned research teams reviewed each candidate best paper, and (iii) the final selection of three best papers was conducted by the editorial board of the Yearbook.
Results:
Results: The three selected best papers present studies addressing many facets of cancer informatics, with immediate applicability in the research and clinical domains.
Conclusion:
Cancer informatics is a broad and vigorous subfield of biomedical informatics. Strides in knowledge management, crowdsourcing, and visualization are especially notable in 2017.
Collapse
Affiliation(s)
- Jeremy L Warner
- Associate Professor, Departments of Medicine and Biomedical Informatics, Vanderbilt University, Nashville, TN, USA
| | | | | |
Collapse
|
29
|
Oliveira M, Saura C, Calvo I, Andersen J, Coelho JLP, Gil MG, Bermejo B, Patt DA, Ciruelos E, Singel SM, Maslyar DJ, Wongchenko M, Chan WY, Kapp AV, Peña LDL, Baselga J, Isakoff SJ. Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC). Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-ct041] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: This hypothesis-generating trial evaluated neoadjuvant IPAT + PAC for eTNBC.
Methods: Patients (pts) with eTNBC, T ≥1.5 cm and N0-2 were randomized 1:1 to receive 12 wks of weekly PAC 80 mg/m² + either IPAT 400 mg or PBO d1-21 q28d before surgery. Investigators chose adjuvant therapy. Stratification factors were PTEN status (Targos IHC), nodal status and tumor size. Co-primary endpoints were pathologic complete response (pCR) rate (ypT0/TisN0) in the intent-to-treat (ITT) and PTEN-low (Ventana IHC) populations. Secondary endpoints included pCR rate in pts with PIK3CA/AKT1/PTEN-altered tumors (NGS; Foundation Medicine), pre-surgery clinical response rates by MRI and safety.
Results: From Feb 2015 to Mar 2017, 151 pts were randomized. Most had T1/2 (87%) N0 (65%) tumors. At the final analysis (9 Nov 2017), 132 pts (87%) had completed surgery. In all 3 populations, rates of pCR, overall clinical response and complete response (CR) by MRI favored IPAT (Table). IPAT was associated with more grade ≥3 AEs (32% vs 16% with PBO), especially diarrhea (17% vs 1%). AEs leading to IPAT/PBO discontinuation (9% vs 3%) or dose reduction (16% vs 1%) or PAC interruption (20% vs 12%) were more common with IPAT but median PAC dose intensity was 100% (IQR 100-100%) in both arms. Incidences of neuropathy (57% vs 61%) and neutropenia (14% vs 13%) were similar with IPAT vs PBO.
Conclusions: Adding IPAT to PAC for eTNBC showed a small non-significant increase in pCR rate. The anti-tumor effect of IPAT was most pronounced in biomarker-selected pts: CR rates were 32% vs 6% in pts with PTEN-low tumors and 39% vs 9% in PIK3CA/AKT1/PTEN-altered tumors. Safety was consistent with prior IPAT + PAC experience. Similar to LOTUS in metastatic TNBC, FAIRLANE results support further evaluation of IPAT + PAC in pts with PIK3CA/AKT1/PTEN-altered tumors. A comprehensive translational research program is ongoing.
TableEndpointITTPTEN-low (by IHC)PIK3CA/AKT1/PTEN-altered (by NGS)IPAT + PACPBO + PACIPAT + PACPBO + PACIPAT + PACPBO + PACpCR rate (ypT0/TisN0)13/76 (17.1%)10/75 (13.3%)3/19 (15.8%)2/16 (12.5%)5/28 (17.9%)4/34 (11.8%)Difference (95% CI)3.8% (-9.0 to 16.5)3.3% (-25.5 to 32.1)6.1% (-15.0 to 27.2)Overall clinical response ratea by MRI51/76 (67.1%)42/75 (56.0%)14/19 (73.7%)8/16 (50.0%)19/28 (67.9%)18/34 (52.9%)Difference (95% CI)11.1% (-5.6 to 27.9)23.7% (-13.6 to 60.9)14.9% (-12.4% to 42.3%)CR rateb by MRI21/76 (27.6%)10/75 (13.3%)6/19 (31.6%)1/16 (6.3%)11/28 (39.3%)3/34 (8.8%)aUnconfirmed complete or partial response. bUnconfirmed complete response.
Citation Format: Mafalda Oliveira, Cristina Saura, Isabel Calvo, Jay Andersen, José Luis Passos Coelho, Miguel Gil Gil, Begoña Bermejo, Debra A. Patt, Eva Ciruelos, Stina M. Singel, Daniel J. Maslyar, Matthew Wongchenko, Wai Y. Chan, Amy V. Kapp, Lorena de la Peña, José Baselga, Steven J. Isakoff. Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT041.
Collapse
Affiliation(s)
- Mafalda Oliveira
- 1Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain
| | - Cristina Saura
- 1Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain
| | - Isabel Calvo
- 2Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain
| | - Jay Andersen
- 3Northwest Cancer Specialists – Portland, US Oncology, Portland, OR
| | | | - Miguel Gil Gil
- 5Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain
| | | | - Debra A. Patt
- 7Texas Oncology Cancer Center, US Oncology, Austin, TX
| | - Eva Ciruelos
- 8University Hospital 12 de Octubre and SOLTI Breast Cancer Research Group, Madrid, Spain
| | | | | | | | | | | | | | - José Baselga
- 11Memorial Sloan Kettering Cancer Center, New York, NY
| | | |
Collapse
|
30
|
Rugo HS, Tolaney SM, Cortés J, Diéras V, Patt DA, Wildiers H, Nanda S, Koustenis AG, Dickler MN, Baselga J. Abstract CT044: MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-ct044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Abemaciclib is an oral, selective inhibitor of CDK4 and CDK6 dosed on a continuous schedule. MONARCH 1 (NCT02102490) is a phase 2 single-arm study designed to evaluate safety and efficacy of abemaciclib monotherapy in women with HR+/HER2- MBC whose disease progressed on or after endocrine therapy and chemotherapy. Final analysis of the primary endpoint, objective response rate (ORR) at 12 months (mo), showed that abemaciclib monotherapy induced objective tumor responses in patients (pts) with refractory HR+/HER2- MBC following multiple prior therapies. Treatment was well tolerated, allowing prolonged exposure to therapy. We report the final 18 mo overall survival results.
Methods: Eligible pts had measurable disease, ECOG PS of 0/1, no CNS metastases, and received at least 1 but no more than 2 lines of chemotherapy in the metastatic setting. Abemaciclib (200 mg) was administered orally on a continuous schedule every 12 hours until disease progression. The primary objective was to evaluate ORR per RECIST v1.1. at 12 mo after the last pt enrolled. Secondary objectives included duration of response (DoR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR = CR + PR + SD), clinical benefit rate (CBR= CR + PR + SD ≥ 6 mo) and safety. Final OS analysis occurred 18 mo after the last pt was enrolled.
Results: A total of 132 pts received abemaciclib monotherapy. The primary endpoint of ORR by investigator assessment at 12 mo was 19.7% (95% CI: 13.3, 27.5) and did not change at 18 mo. Of the 26 responding pts, 19 (73.1%) had responses ≥ 6 mo, and 6 pts still on treatment have response durations ranging from 9.5+ to 20.5+ mo. There was no change at 18 mo vs 12 mo for DCR (67.4%) or CBR (42.4%). Median PFS (6.0 mo, 95% CI: 4.2, 7.5) and median DoR (8.9 mo, 95% CI: 6.1, 14.0) were also consistent with 12 mo follow up. At the 18 mo update, 7 pts (5.3%) remained on treatment (6 PR and 1 SD). At 18 mo, the median OS was 22.3 mo (95% CI: 17.7, NR), and the survival rate was 58.7%. TEAEs ≥ Grade 3 were experienced by 93 pts (70.5%) at 18 mo, compared to 90 pts (68.2%) at 12 mo. The most common Grade 3/4 TEAEs were neutropenia (25.0%), diarrhea (19.7%), fatigue (13.6%), leukopenia (6.8%), anemia (4.5%) and nausea (4.5%). Treatment discontinuations due to AEs were infrequent (7.6 %).
Conclusions: The results of the 18 month analysis are consistent with the 12 month results of MONARCH 1. Median OS was 22.3 months. The efficacy results from the MONARCH 1 study indicate that continuous administration of single-agent abemaciclib induces durable confirmed tumor responses. There were no clinically significant changes in safety. The results of the 18 month analysis support the earlier results and indicate that single-agent abemaciclib may offer a more favorable benefit-risk profile than expected from available cytotoxic chemotherapies.
Citation Format: Hope S. Rugo, Sara M. Tolaney, Javier Cortés, Véronique Diéras, Debra A. Patt, Hans Wildiers, Shivani Nanda, Andrew G. Koustenis, Maura N. Dickler, José Baselga. MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT044. doi:10.1158/1538-7445.AM2017-CT044
Collapse
Affiliation(s)
- Hope S. Rugo
- 1University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - Sara M. Tolaney
- 2Dana-Farber Cancer Institute, The Brigham and Women’s Hospital Corporation, Boston, MA
| | - Javier Cortés
- 3Vall d'Hebron Institute of Oncology and Ramón y Cajal University Hospital, Barcelona and Madrid, Spain
| | | | | | | | | | | | | | - José Baselga
- 9Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
31
|
Cowey CL, Liu FX, Black-Shinn J, Stevinson KL, Boyd M, Patt DA, Ebbinghaus S. An observational study of patients with advanced melanoma receiving pembrolizumab in a real-world U.S. community oncology practice. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e21015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21015 Background: PD-1 monoclonal antibodies are promising immunotherapies approved for treatment of patients (pts) with advanced melanoma. As the first US FDA approved PD-1 antibody, pembrolizumab (pembro) has demonstrated efficacy and safety in clinical trial settings. However, patterns of real world utilization and pt outcomes associated with pembro are limited. Methods: Adult pts with advanced melanoma who initiated pembro between 9/1/ 2014-3/31/2016 were identified retrospectively fromelectronic health records (EHR) of McKesson Specialty Health and followed through 9/ 30/2016. Pts in clinical trials were excluded. Demographic, disease, treatment characteristics and reasons for treatment discontinuation of pembro were abstracted from structured data elements of the EHR with further supplementation of unstructured data within the patient chart (progress notes, radiology scan reports). Overall survival (OS) and physician-reported progression free survival (PFS) from pembro initiation were analyzed using Kaplan Meier analysis. Results: 182 pts, with a median follow-up of 9.9 mos (range = 0.0-25.0), were included. Median age at pembro initiation was 66.0 yrs; 30.8% had an elevated lactate dehydrogenase (LDH); 23.6% had brain metastases and 65.4% had an ECOG performance status of 0 or 1. The most common reason for pembro discontinuation was progression (45.5%) followed by treatment-related toxicity (24.4%). In the overall population, median PFS from pembro initiation was 4.2 mos (95% CI = 3.2-5.3). Median OS was 19.4 mos (14.0-NR) with 12 and 24-month survival probabilities of 61.4% (95% CI = 53.4-68.5) and 43.9% (95% CI = 31.1-55.9). In multivariable analyses, characteristics predictive of worse survival included receipt of pembro at a later line of therapy (HR = 3.36, p = 0.0013 for 3L+), presence of brain metastases (HR = 2.67, p = 0.0007) and elevated LDH (HR = 4.10, p < 0.0001). Conclusions: The study results are consistent with those from pembro clinical trials (KeyNote001) and are in support of the effectiveness of pembro in real world treatment of advanced melanoma. Presence of brain metastases, elevated LDH, and use of pembro 3L+ were associated with worse survival outcome.
Collapse
Affiliation(s)
- Charles Lance Cowey
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX
| | | | | | | | - Marley Boyd
- The US Oncology Network, McKesson Specialty Health, The Woodlands, TX
| | - Debra A. Patt
- McKesson Specialty Health/US Oncology Network, The Woodlands, TX
| | | |
Collapse
|
32
|
Ma Q, Agiro A, Acheson AK, Wu SJ, Patt DA, Barron J, Rosenberg A, Schilsky RL, Lyman GH. Neutropenia related hospitalization risk in lung cancer patients with chemotherapy. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e18290] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18290 Background: We sought to describe outcomes following granulocyte-colony stimulating factor (G-CSF) prophylaxis in patients with lung cancer receiving chemotherapy regimens with low to intermediate risk for inducing neutropenia related hospitalization. Methods: We identified 11,233 lung cancer (all histologies) patients ≥ 18 years from 14 commercial US health plans. All patients received first cycle chemotherapy during 2008–2013. 5,423 patients received one of the 3 regimens: carboplatin and paclitaxel, cisplatin and etoposide, carboplatin and etoposide. Primary prophylaxis (PP) was defined as G-CSF administration within 5 days of chemotherapy. Outcome was neutropenia, fever, or infection-related hospitalization within 21 days. Regression and number-needed-to-treat (NNT) analyses were used. Results: A total of 11,233 patients received any chemotherapy (21.2% PP), were older (median years 64 PP; 64 no PP) and had at least 1 non-cancer comorbidity (79.8% PP; 77.9% no PP). About 2,776 patients received Carbo/Paclitaxel (13.9% PP), 1,356 patients received Cisp/Etop (23% PP) and 1,291 patients received Carbo/Etop (45.8% PP) regimens. PP was associated with lower risk of neutropenia related hospitalization for any chemotherapy (4.7% PP; 7.5% no PP; odds ratio [OR] 0.61; 95% CI 0.49 – 0.74), for Cisp/Etop (5.1% PP; 8.8% no PP; OR 0.56; 95% CI 0.32 – 0.97) and Carbo/Etop (5.6% PP; 11% no PP; OR 0.48; 95% CI 0.31 – 0.73), but not Carbo/Paclitaxel (5.7% PP; 6.7% no PP; OR 0.84; 95% CI 0.53 – 1.32) regimens. Based on NNT, the total cost of PP for 36 patients with any chemotherapy regimen to avoid one hospitalization would be $128,952 (mean hospitalization cost = $11,900, Standard Deviation [SD] = $9,541). For 28 patients with Cisp/Etop, it would be $101,920 (mean hospitalization cost = $16,957, SD = $16,135). For 19 patients with Carbo/Etop, it would be $63,270 (mean hospitalization cost = $11,356, SD = $6,949). Conclusions: Primary G-CSF prophylaxis was associated with some benefit in lowering neutropenia-related hospitalization in patients with lung cancer receiving Cisp/Etop and Carbo/Etop regimens, although the cost to treat patients remains high. Future studies need to examine the value of continued G-CSF use in subsequent cycles.
Collapse
Affiliation(s)
- Qinli Ma
- HealthCore, Translational Research for Affordability and Quality (TRAQ), Wilmington, DE
| | - Abiy Agiro
- HealthCore, Translational Research for Affordability and Quality (TRAQ), Wilmington, DE
| | | | - Sze-Jung Wu
- HealthCore, Life Sciences Research, Wilmington, DE
| | - Debra A. Patt
- McKesson Specialty Health/US Oncology Network, The Woodlands, TX
| | | | | | | | | |
Collapse
|
33
|
Patt DA, Howell J, Neubauer MA, He B, Garey JS. Measuring quality in cancer care: Utilizing a clinical decision support system to assess pathway adherence. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.8_suppl.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
172 Background: Quality-based programs depend on clinical data documentation for reporting, treatment planning, and measuring pathways (PW) compliance. Adherence to treatment PW reduces variability and costs of care. Clinical decision support systems (CDSS) are tools embedded in the EHR to capture assessable data: stage, biomarkers, line of therapy, etc. With such data, CDSS can measure and report on clinical quality improvement programs like PW adherence, assessable data and exception reporting. Methods: A retrospective cohort study from Jan 1, 2014 - May 30, 2016 measured the impact of an integrated CDSS assessing compliance to PW and exception reporting across 9 independent oncology practices over a 9 month period. Assessable data, PW adherence, and exception reporting were tracked in 4 month intervals pre and post CDSS intervention by practice and physician. A one month wash out period was included post CDSS implementation. Overall rates of positivity, assessable data, and exception reporting were compared pre and post intervention using the Chi-square test. To account for the effect of time on the intervention, a segmented regression analysis was performed to analyze weekly rates of positivity pre and post intervention. Results: 9 practices, 633 physicians, and 30,666 treatment regimens were included. The weekly adherence rate increased by 7.2% after intervention (p = 0.005) across the group. Assessable data capture significantly improved across the cohort OR 6.79 (5.64-8.16) and individually for most practices. Physicians adherent to PW 75% of the time increased post intervention collectively, OR 1.83 (1.44-2.31), and individually. Exception reporting improved from 29% to 99% (p<0.0001). Conclusions: Across a cohort of community oncology practices rates of assessable data, PW adherence, and exception reporting improved after implementation of an integrated CDSS. Effective CDSSs are a critical component of quality improvement programs and may be used to improve data capture, increase adherence to PW and overall contribute to quality cancer care delivery. [Table: see text]
Collapse
Affiliation(s)
- Debra A. Patt
- McKesson Specialty Health-The US Oncology Network, The Woodlands, TX
| | - Josh Howell
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | | | - Bo He
- McKesson Specialty Health, The Woodlands, TX
| | | |
Collapse
|
34
|
Patt DA, Bernstam EV, Mandel JC, Kreda DA, Warner JL. More Medicine, Fewer Clicks: How Informatics Can Actually Help Your Practice. Am Soc Clin Oncol Educ Book 2017; 37:450-459. [PMID: 28561658 DOI: 10.1200/edbk_174891] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
In the information age, we expect data systems to make us more effective and efficient-not to make our lives more difficult! In this article, we discuss how we are using data systems, such as electronic health records (EHRs), to improve care delivery. We illustrate how US Oncology is beginning to use real-world evidence to facilitate trial accrual by automatic identification of eligible patients and how big data and predictive analytics will transform the field of oncology. Some information systems are already being used at the point of care and are already empowering clinicians to improve the care of their patients in real time. Telehealth platforms are being used to bridge gaps that currently exist in expertise, geography, and technical capability. Optimizing virtual collaboration, such as through virtual tumor boards, is empowering communities that are geographically disparate to coordinate care. Informatics methods can provide solutions to the challenging problems of how to manage the vast amounts of data confronting the practicing oncologist, including information about treatment regimens, side effects, and the influence of genomics on the practice of oncology. We also discuss some of the challenges of clinical documentation in the modern era, and review emerging efforts to engage patients as digital donors of their EHR data.
Collapse
Affiliation(s)
- Debra A Patt
- From Texas Oncology, Austin, TX, McKesson Specialty Health and the US Oncology Network, The Woodlands, TX; School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX; Verily (Google Life Sciences), USA Research Faculty, Harvard Medical School, Cambridge, MA; Vanderbilt University, Vanderbilt Cancer Registry, Nashville, TN
| | - Elmer V Bernstam
- From Texas Oncology, Austin, TX, McKesson Specialty Health and the US Oncology Network, The Woodlands, TX; School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX; Verily (Google Life Sciences), USA Research Faculty, Harvard Medical School, Cambridge, MA; Vanderbilt University, Vanderbilt Cancer Registry, Nashville, TN
| | - Joshua C Mandel
- From Texas Oncology, Austin, TX, McKesson Specialty Health and the US Oncology Network, The Woodlands, TX; School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX; Verily (Google Life Sciences), USA Research Faculty, Harvard Medical School, Cambridge, MA; Vanderbilt University, Vanderbilt Cancer Registry, Nashville, TN
| | - David A Kreda
- From Texas Oncology, Austin, TX, McKesson Specialty Health and the US Oncology Network, The Woodlands, TX; School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX; Verily (Google Life Sciences), USA Research Faculty, Harvard Medical School, Cambridge, MA; Vanderbilt University, Vanderbilt Cancer Registry, Nashville, TN
| | - Jeremy L Warner
- From Texas Oncology, Austin, TX, McKesson Specialty Health and the US Oncology Network, The Woodlands, TX; School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX; Verily (Google Life Sciences), USA Research Faculty, Harvard Medical School, Cambridge, MA; Vanderbilt University, Vanderbilt Cancer Registry, Nashville, TN
| |
Collapse
|
35
|
Abstract
Mentorship can be the cornerstone of professional development and career satisfaction. There is literature to support that mentorship not only improves job satisfaction, but also improves productivity, facilitates personal growth, and can rekindle our passion while lessening the risk of compassion fatigue. Mentorship is a developmental relationship that changes as the relationship evolves. There are two broad categories of mentorship: traditional and transformational. There are four subtypes within each of those areas: formal, informal, spot, or peer. Mentorship is critical to the professional development of junior colleagues. Good mentorship is guiding and steering younger partners and other colleagues toward paths of success. As a mentor, one should be looking for opportunities for formal professional development and engagement of mentees. Self-motivation is the hallmark of the successful mentee. The mentee should be able to set his or her own goals, strive to actively seek feedback, ask questions, and keep an accurate record of progress. Although the onus is on the mentee to reach out, mentorship has bidirectional value directly related to the efforts of both parties. There are many benefits to mentorship, such as the promotion of learning, personal development, improved job satisfaction, and improved job performance. Barriers exist, including the rapidly changing landscape of oncology, time constraints, lack of self-awareness, and generational differences. Through a career, mentoring needs will change, as will mentors.
Collapse
Affiliation(s)
- Kelly J Cooke
- From the UW Cancer Center at ProHealth Care, Waukesha, WI; The US Oncology Network/McKesson Specialty Health, Austin, TX; Southeast Radiation Oncology Group/Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC
| | - Debra A Patt
- From the UW Cancer Center at ProHealth Care, Waukesha, WI; The US Oncology Network/McKesson Specialty Health, Austin, TX; Southeast Radiation Oncology Group/Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC
| | - Roshan S Prabhu
- From the UW Cancer Center at ProHealth Care, Waukesha, WI; The US Oncology Network/McKesson Specialty Health, Austin, TX; Southeast Radiation Oncology Group/Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC
| |
Collapse
|
36
|
Agiro A, Ma Q, Acheson AK, Wu SJ, Patt DA, Barron JJ, Malin JL, Rosenberg A, Schilsky RL, Lyman GH. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. J Clin Oncol 2016; 34:3872-3879. [DOI: 10.1200/jco.2016.67.2899] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxis in patients with breast cancer who received chemotherapy regimens with low-to-intermediate risk of induction of neutropenia-related hospitalization. Patients and Methods We identified 8,745 patients age ≥ 18 years from a medical and pharmacy claims database for 14 commercial US health plans. This retrospective analysis included patients with breast cancer who began first-cycle chemotherapy from 2008 to 2013 using docetaxel and cyclophosphamide (TC); docetaxel, carboplatin, and trastuzumab (TCH); or doxorubicin and cyclophosphamide (conventional-dose AC) regimens. Primary prophylaxis (PP) was defined as G-CSF administration within 5 days of beginning chemotherapy. Outcome was neutropenia, fever, or infection-related hospitalization within 21 days of initiating chemotherapy. Multivariable regressions and number-needed-to-treat analyses were used. Results A total of 4,815 patients received TC (2,849 PP; 1,966 no PP); 2,292 patients received TCH (1,444 PP; 848 no PP); and 1,638 patients received AC (857 PP; 781 no PP) regimen. PP was associated with reduced risk of neutropenia-related hospitalization for TC (2.0% PP; 7.1% no PP; adjusted odds ratio [AOR], 0.29; 95% CI, 0.22 to 0.39) and TCH (1.3% PP; 7.1% no PP; AOR, 0.19; 95% CI, 0.12 to 0.30), but not AC (4.7% PP; 3.8% no PP; AOR, 1.21; 95% CI, 0.75 to 1.93) regimens. For the TC regimen, 20 patients (95% CI, 16 to 26) would have to be treated for 21 days to avoid one neutropenia-related hospitalization; with the TCH regimen, 18 patients (95% CI, 13 to 25) would have to be treated. Conclusion Primary G-CSF prophylaxis was associated with low-to-modest benefit in lowering neutropenia-related hospitalization in patients with breast cancer who received TC and TCH regimens. Further evaluation is needed to better understand which patients benefit most from G-CSF prophylaxis in this setting.
Collapse
Affiliation(s)
- Abiy Agiro
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - Qinli Ma
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - Anupama Kurup Acheson
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - Sze-jung Wu
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - Debra A. Patt
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - John J. Barron
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - Jennifer L. Malin
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - Alan Rosenberg
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - Richard L. Schilsky
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| | - Gary H. Lyman
- Abiy Agiro, Qinli Ma, Sze-jung Wu, and John J. Barron, HealthCore, Wilmington, DE; Anupama Kurup Acheson, Providence Cancer Center, Portland, OR; Debra A. Patt, Texas Oncology, Austin; Debra A. Patt, The US Oncology Network, Houston, TX; Jennifer L. Malin, Anthem, Woodland, CA; Alan Rosenberg, Anthem, Chicago, IL; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research and University of Washington, Seattle, WA
| |
Collapse
|
37
|
Patt DA, Jiao X, Fonseca E, Clark J, Fox PS, Horblyuk R, McRoy L, Mardekian J, Arondekar B. Real-world use of first-line chemotherapy in post-menopausal patients with HR-positive HER2-negative metastatic breast cancer (mBC) in a US community oncology network. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Debra A. Patt
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | - Xiaolong Jiao
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | - Eileen Fonseca
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | - Jamyia Clark
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | - Patricia S. Fox
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | | | | | | | | |
Collapse
|
38
|
Isakoff SJ, Saura C, Calvo I, Gil Gil MJ, Patt DA, Morales Murillo S, Andersen JC, Ciruelos EVA, Fisher JG, Passos-Coelho J, de La Pena L, Kapp AV, Gendreau S, Chan WY, Singel SM, Maslyar DJ, Baselga J, Oliveira M. FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.tps1105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Cristina Saura
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Isabel Calvo
- Centro Integral Oncológico Clara Campal, Madrid, Spain
| | | | - Debra A. Patt
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | | | | | - EVA Ciruelos
- Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | | | | | | | | | | | | | | | - Jose Baselga
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | |
Collapse
|
39
|
Patt DA, Mitra D, Harrell RK, Espirito JL, Perkins JJ, McRoy L, Arondekar B. Early treatment utilization of palbociclib for metastatic breast cancer (MBC) in a U.S. community oncology network. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e18112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Debra A. Patt
- The US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | | | - Robyn K. Harrell
- The US Oncology Network, McKesson Specialty Health, The Woodlands, TX
| | | | | | | | | |
Collapse
|
40
|
Dickler MN, Tolaney SM, Rugo HS, Cortes J, Diéras V, Patt DA, Wildiers H, Frenzel M, Koustenis A, Baselga J. MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.510] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Hope S. Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Javier Cortes
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | | | - Hans Wildiers
- University Hospitals Leuven and KU Leuven, Leuven, Belgium
| | | | | | - Jose Baselga
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
41
|
Patt DA, Fonseca E, Yoo B, Wilson T, Goertz HP, Lai C. Real-world treatment patterns and outcomes in HER2 positive MBC patients with brain metastasis in the U.S. community oncology setting. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.7_suppl.92] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
92 Background: Patients (pts) with HER2 positive (HER2+) metastatic breast cancer (MBC) have different patterns of disease and treatment (tx) from HER2 negative MBC. Brain metastasis (BM) frequently occurs and txs vary. Methods: This retrospective study included adult HER2+ MBC pts from a community oncology network electronic health record (EHR) database and diagnosed between 2009-2011, with follow-up until 11/2014. Pts with other primary tumors were excluded. Two cohorts were defined: pts diagnosed with BM and pts with no evidence of BM (NBM), and were initially matched on age and performance status at MBC diagnosis (dx) and stage. Eligibility and txs were examined in electronic chart review. Overall survival (OS) from MBC dx was estimated using a weighted Kaplan-Meier method. Results: The final sample consisted of 86 BM and 101 NBM pts. All baseline MBC demographics were similar across cohorts. Median age was 54 and 52 years for BM and NBM, respectively. The cohorts (BM:NBM) included 57%:75% Caucasians, 12%:6% Blacks, and 31%:19% other/unknown. There were fewer estrogen receptor positive pts in the BM cohort (58%:74%; p = 0.02). Except for bone (p = 0.01), both cohorts had similar prevalence of metastatic sites: liver 35%:35%; lung 31%:30%; bone 41%:62. Of all the BM pts, 54% had first CNS imaging after symptoms, 37% were first imaged for other known reasons. After BM dx, 20% had surgical resection, 67% whole brain radiation (XRT), 37% stereotactic XRT, and 22% palliative XRT (not mutually exclusive). 25% of pts had both XRT and surgery while 72% had only XRT. Among pts receiving systemic therapy after BM dx, the first regimen contained trastuzumab in 55% of pts and lapatinib in 41% of pts. Among pts changing txs after BM dx, 1/3 switched to a trastuzumab but not lapatinib-based regimen; 1/3 to a lapatinib but not trastuzumab-based regimen; 17% to a lapatinib + trastuzumab-based regimen; and 17% to non-HER2-based therapy. Weighted median OS from MBC dx for BM vs. NBM pts was 30.2 and 46.1 months (p = 0.01). Conclusions: For HER2+ MBC pts, survival was shorter for pts with BM vs. NBM and a high degree of tx variability for BM existed. Understanding how detection and tx impacts outcomes will improve care of BM pts.
Collapse
Affiliation(s)
| | | | - Bongin Yoo
- Genentech, Inc., South San Francisco, CA
| | | | | | | |
Collapse
|
42
|
Patt DA, Stergiopoulos SG, Hippert R, Harrell RK, Espirito JL, Squier P, Ko A. Outcomes by schedule and line of therapy in patients (pts) with metastatic breast cancer (MBC) treated with nab-paclitaxel ( nab-P): A U.S. retrospective, community-based, real-world cohort analysis. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.7_suppl.86] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
86 Background: In a phase III study in MBC, nab-P showed activity across lines of therapy. nab-P is approved for MBC at 260 mg/m2 every 3 weeks (q3w). This analysis evaluated outcomes with use of nab-P in MBC by schedule and line of therapy in a U.S. community setting. Methods: A multicenter, retrospective cohort analysis was conducted using iKnowMed electronic health record data and electronic medical chart review of women with ≥ 5 visits to a site in the US Oncology Network. Vital status was supplemented by the Social Security Death Index. Pts with MBC treated with nab-P between April 1, 2011, and February 1, 2013, were followed through August 1, 2013. Pts diagnosed with another primary cancer or with prior nab-P use were excluded. Data were analyzed by line (first [1L] vs ≥ second [≥2L]) or schedule (weekly [qw] vs q3w) based on the first therapy (index therapy) received in the study period. The usage pattern of index therapy was described by pt demographics and baseline characteristics. Effectiveness of index therapy was assessed by adjusted duration of treatment (DOT; time from first to last date of treatment + 6 days for qw and 20 days for q3w [to reflect true treatment duration]), time to new treatment (TTNT; time from start of index therapy), and overall survival (OS; time from start of index therapy). Analyses of other efficacy/safety endpoints, healthcare utilization, and corresponding costs will be performed. Results: 766 pts were included; 333 and 433 initiated index therapy as 1L and ≥ 2L, and 650 and 116 received index therapy qw and q3w. 76% received nab-P monotherapy. Most pts were < 65 years (64%), HER2− (76%), ER+ (76%), ER+/HER2− (60%), and postmenopausal (79%). 16% had triple-negative MBC. No notable differences in pt characteristics between the 1L/≥ 2L or qw/q3w groups were seen. Sensory neuropathy rates were 35% vs 39% for the 1L and ≥ 2L and 36% vs 45% for qw vs q3w. Conclusions: This analysis of a community-based cohort indicated that nab-P was primarily used as monotherapy on a qw schedule and in the ≥ 2L setting. [Table: see text]
Collapse
Affiliation(s)
| | | | | | - Robyn K. Harrell
- The US Oncology Network, McKesson Specialty Health, The Woodlands, TX
| | | | | | - Amy Ko
- Celgene Corporation, Summit, NJ
| |
Collapse
|
43
|
Mikan SQ, Carter P, Patt DA. Advanced practice providers and survivorship care plans. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.3_suppl.70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
70 Background: The American College of Surgeons mandate in 2012 challenged organizations to create and develop quality survivorship care programs. The NCCN and Commission on Cancer set the standard for quality psychosocial care recognizing distress as part of the cancer continuum. In order to meet this challenge, community cancer care organizations are incorporating delivery of survivorship and psychosocial care into the Advanced Practice Provider (APP) role. APPs include Physician Assistants (PAs) and Advanced Practice Nurses (APNs). We describe the development and feasibility testing of an APP-led survivorship program in a large network of community oncology practices. Methods: A descriptive study design was used with ten practices participating in the implementation of a structured APP-led survivorship program. The goals of each survivorship visit were to: review recommendations for care and healthy lifestyle behaviors, review surveillance recommendations, and to reconnect patients with their primary care providers. Nineteen APPs in the study site practices offered survivorship management between October 2012 and May 2015 to female breast and colon cancers at all stages. Results: Study sites used structured process maps to identify and refer patients to survivorship visits. Evaluations of additional referral strategies are ongoing. Participating APPs reported high self-efficacy in delivering survivorship care plans and high patient satisfaction following visits. All female breast or colon cancer patients, regardless of stage at diagnosis, attended the appointment and received a complete care plan based upon the ASCO Survivorship Care Plan. Surveillance education was provided specific to diagnosis utilizing the NCCN guidelines delivering person-centered care. Visits lasted an average of 60 minutes and were billable as counseling and coordination. Conclusions: Patients diagnosed with breast or colon cancer make up the largest majority of cancer survivors. This project reveals that an APP-led survivorship program is feasible and can help to meet the ASCO and NCCN challenge of providing survivorship care to this large population.
Collapse
|
44
|
Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, Morrow PK, Barron RL, Asmar L, Saravanan S, Li Y, Garcia J, Lyman GH. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. J Natl Compr Canc Netw 2015; 13:1383-93. [DOI: 10.6004/jnccn.2015.0166] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
45
|
Henry NL, Patt DA, Meyers MO, Malik M, Bretsch J, Jackson C, Grupe A, Von Roenn J. Bridging the Medical Education and Quality Cancer Care Divide: A Call to Action. J Oncol Pract 2015; 11:424-6. [PMID: 26130819 DOI: 10.1200/jop.2015.004242] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
ASCO Leadership Development Program members were tasked by the ASCO Board of Directors to explore how to optimize integration of key aspects of oncology care in order to facilitate continuous quality improvement for the practicing oncologist. This Perspective summarizes their findings.
Collapse
Affiliation(s)
- N Lynn Henry
- University of Michigan Medical School, Ann Arbor, MI; Texas Oncology, Austin, TX; University of North Carolina School of Medicine, Chapel Hill, NC; Nizam's Institute of Medical Sciences, Hyderabad, India; and American Society of Clinical Oncology, Alexandria, VA
| | - Debra A Patt
- University of Michigan Medical School, Ann Arbor, MI; Texas Oncology, Austin, TX; University of North Carolina School of Medicine, Chapel Hill, NC; Nizam's Institute of Medical Sciences, Hyderabad, India; and American Society of Clinical Oncology, Alexandria, VA
| | - Michael O Meyers
- University of Michigan Medical School, Ann Arbor, MI; Texas Oncology, Austin, TX; University of North Carolina School of Medicine, Chapel Hill, NC; Nizam's Institute of Medical Sciences, Hyderabad, India; and American Society of Clinical Oncology, Alexandria, VA
| | - Monica Malik
- University of Michigan Medical School, Ann Arbor, MI; Texas Oncology, Austin, TX; University of North Carolina School of Medicine, Chapel Hill, NC; Nizam's Institute of Medical Sciences, Hyderabad, India; and American Society of Clinical Oncology, Alexandria, VA
| | - Jennifer Bretsch
- University of Michigan Medical School, Ann Arbor, MI; Texas Oncology, Austin, TX; University of North Carolina School of Medicine, Chapel Hill, NC; Nizam's Institute of Medical Sciences, Hyderabad, India; and American Society of Clinical Oncology, Alexandria, VA
| | - Carmen Jackson
- University of Michigan Medical School, Ann Arbor, MI; Texas Oncology, Austin, TX; University of North Carolina School of Medicine, Chapel Hill, NC; Nizam's Institute of Medical Sciences, Hyderabad, India; and American Society of Clinical Oncology, Alexandria, VA
| | - Anne Grupe
- University of Michigan Medical School, Ann Arbor, MI; Texas Oncology, Austin, TX; University of North Carolina School of Medicine, Chapel Hill, NC; Nizam's Institute of Medical Sciences, Hyderabad, India; and American Society of Clinical Oncology, Alexandria, VA
| | - Jamie Von Roenn
- University of Michigan Medical School, Ann Arbor, MI; Texas Oncology, Austin, TX; University of North Carolina School of Medicine, Chapel Hill, NC; Nizam's Institute of Medical Sciences, Hyderabad, India; and American Society of Clinical Oncology, Alexandria, VA
| |
Collapse
|
46
|
Vogelzang NJ, Asmar L, Tang J, Yap M, Todd MB, Ng Y, Mehra M, Patt DA. Abiraterone acetate followed by enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) treated in the US Oncology Community Setting. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e16061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Lina Asmar
- McKesson Specialty Health, The Woodlands, TX
| | - Jun Tang
- McKesson Specialty Health, The Woodlands, TX
| | - Mark Yap
- McKesson Specialty Health, The Woodlands, TX
| | | | | | | | | |
Collapse
|
47
|
Yasenchak CA, Tseng WY, Yap M, Rembert D, Patt DA. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leuk Lymphoma 2015; 56:3143-9. [PMID: 25860233 DOI: 10.3109/10428194.2015.1030639] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The current study aimed to assess the economic burden of progressive disease among patients with Hodgkin lymphoma (HL) receiving second- or third-line therapy in a large US network of community-based practices. This retrospective, observational cohort analysis used electronic health records to examine adult patients with classical HL who received chemotherapy between 2007 and 2011. Of 291 observations, 112 had non-progressive disease (received only one line of therapy; LOT1), 114 received second-line therapy (LOT2), and 65 received third-line therapy (LOT3). In LOT2, 49 patients (43%) underwent transplant. In LOT3, 13 patients (20%) underwent transplant. The mean total cost per line of therapy was $21 956 in LOT1, $77 219 in LOT2, and $59 442 in LOT3. When transplant was required, the mean total cost per line of therapy increased 7- to 8-fold when compared with the cost of LOT1 (approximately $154 000 for LOT2 and $193 000 for LOT3). Future therapies that intervene as early as possible in the treatment algorithm to prevent or significantly delay relapse will likely result in significant cost savings.
Collapse
Affiliation(s)
- Christopher A Yasenchak
- a Willamette Valley Cancer Institute/The US Oncology Network, McKesson Specialty Health , Springfield , OR , USA.,b McKesson Specialty Health The Woodlands , TX , USA
| | - Wan-Yu Tseng
- b McKesson Specialty Health The Woodlands , TX , USA
| | - Mark Yap
- b McKesson Specialty Health The Woodlands , TX , USA
| | - Debra Rembert
- b McKesson Specialty Health The Woodlands , TX , USA
| | - Debra A Patt
- b McKesson Specialty Health The Woodlands , TX , USA.,c Texas Oncology/The US Oncology Network , Austin , TX , USA
| |
Collapse
|
48
|
Patt DA, Liang C, Li L, Ko A, Duval Fraser C, Corzo D, Enger C. Abstract P3-10-06: Real-world efficacy and safety outcomes of nab-paclitaxel ( nab-P) in patients (pts) with metastatic breast cancer (MBC): Results from a US health insurance database. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p3-10-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: nab-P, an albumin-bound formulation of paclitaxel, was approved in 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 mo of adjuvant chemotherapy based on clinical trials. nab-P demonstrated efficacy and safety when administered weekly in phase II trials and every 3 weeks (q3w) in an international phase III trial. Little is known about the treatment patterns and outcomes of nab-P in the real-world setting. Using health insurance claims data, this study was conducted to characterize efficacy and safety of nab-P in pts with MBC treated in US clinical practices.
Methods: This retrospective claims analysis used data in the Optum Research Database (United Health affiliate). Data were supplemented by Social Security Death Index sources. The analysis included women aged ≥ 18 y with MBC diagnosis (≥ 2 claims of BC diagnosis separated by ≥ 30 d and ≥ 2 claims of metastatic spread) prior to nab-P initiation. Pts had ≥ 6 mo of continuous enrollment in the health plan from January 2005-September 2012, complete medical coverage and pharmacy benefits, no other primary malignancy, and no prior chemotherapy. Cohorts were determined by line of therapy, nab-P regimen, and schedule. Endpoints included treatment patterns, time to next therapy or death (TNTD), overall survival (OS), and safety.
Results: Of the 664 eligible pts, most were between 40-69 y of age (88%) and had received nab-P as ≥ second-line therapy (74%), monotherapy (61%), and weekly dosing (71%). In combination, nab-P was most often given with bevacizumab (58%) or human epidermal growth factor receptor 2 (HER2)–targeted therapy (24%) vs another cytotoxic agent (19%). Median TNTD and OS were 6.1 and 17.4 mo, respectively. By line of therapy (first, second, and ≥ third), TNTD was 7.1, 6.6, and 5.3 mo, and OS was 22.7, 17.4, and 15.1 mo. The OS data are comparable with published clinical trial results (Table). In a subgroup of pts (n = 400) with aggressive disease features (≤ 50 y of age or having ≥ 3 metastases), median OS was 15.6 mo. These data are comparable with a retrospective analysis of pts with visceral dominant metastasis (VDM) or a short disease-free interval (SDFI; Table). Toxicities reported in healthcare claims were consistent with those previously published.
Conclusions: Consistent with clinical trial data, outcomes of this analysis demonstrated the efficacy and safety of nab-P across lines of therapy in a real-world population of patients with MBC.
Clinical Trial Experience in MBC for Pts Treated With nab-PTrialnab-P dose (mg/m2) and schedulenMedian OS, moCA0121 (Ph III)ITT (all lines)260 q3w22915.0≥ second line260 q3w13113.0CA0242 (Ph II, first line)300 q3w7627.7100 qw 3/47622.2150 qw 3/47433.8Median OS, moSubgroups With Aggressive Disease FeaturesnVDMnSDFICA0123 (first line)260 q3w7415.14214.6CA0243 (first line)300 q3w6127.72016.6100 qw 3/46019.62119.1150 qw 3/45932.11418.6qw 3/4, weekly for the first 3 of 4 weeks.
1 Gradishar WJ, et al. J Clin Oncol. 2005;23:7794-7803.
2 Gradishar WJ, et al. Clin Breast Cancer. 2012;12:313-321.
3 O’Shaughnessy J, et al. Breast Cancer Res Treat. 2013;138:829-837.
Citation Format: Debra A Patt, Caihua Liang, Ling Li, Amy Ko, Cindy Duval Fraser, Deyanira Corzo, Cheryl Enger. Real-world efficacy and safety outcomes of nab-paclitaxel (nab-P) in patients (pts) with metastatic breast cancer (MBC): Results from a US health insurance database [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-10-06.
Collapse
|
49
|
Smith DA, Reynolds CH, Patt DA, Smith G, Harrell RK, Horblyuk R, Rembert D, Mardekian J, Yap M, James LP. Patient characteristics and survival outcomes associated with early versus delayed molecular testing in metastatic NSCLC. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.30_suppl.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
211 Background: Evidence-based guidelines recommend molecular testing for appropriate patients with advanced NSCLC at the time of diagnosis of adenocarcinoma. This study evaluated patient demographics, clinical characteristics and survival outcomes associated with early molecular testing (EMT) as compared to delayed molecular testing (DMT) in patients with metastatic NSCLC. Methods: Retrospective analysis of patients’ electronic medical records from The US Oncology Network Practices that utilize iKnowMed (iKM). Patients with a diagnosis of metastatic NSCLC between March 2011 and June 2012, >2 visits and >6 months of follow-up were eligible. EMT and DMT was defined as occurring <45 days and >45 days of diagnosis, respectively. Patient characteristics were compared using t-test and chi-square tests as appropriate. Logistic regression was used to predict the likelihood of higher performance status in the cohorts. Progression-free survival (PFS) and overall survival (OS) were compared using Cox proportional hazards models controlling for age, gender, stage at diagnosis, performance status and comorbidities. Results: A total of 350 patients were eligible and had a median follow-up of 17.3 months. Average age was 64, majority were female (55%) and diagnosed with adenocarcinoma (93%). There were no significant differences in demographic characteristics between EMT and DMT cohorts, however DMT patients were more likely to have ECOG 0 or 1 (OR=2.95, 95%CI=1.33-6.54, p=0.008). No difference in OS or PFS was observed between EMT and DMT patients, p>0.05 (log-rank test). However, poor performance status was found to increase risk of progression/death in multivariate OS and PFS analysis, p<0.02 and p<0.01, respectively. Conclusions: While patients undergoing EMT were nearly three times more likely to exhibit poorer performance status as compared to DMT cohort, their survival outcomes were no different, reinforcing the importance of molecular testing in these patients who may otherwise be less likely to receive treatment. Although limited to small sample size, results of this analysis call for further investigation of potential benefits of EMT in metastatic NSCLC in real-world setting.
Collapse
Affiliation(s)
| | | | | | | | - Robyn K. Harrell
- US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | | | | | | | - Mark Yap
- McKesson Specialty Health, The Woodlands, TX
| | | |
Collapse
|
50
|
Habib JG, Espirito JL, Harrell RK, Turnwald B, O'Shaughnessy J, Patt DA. Secondary nonbreast malignancies (SNBM) after primary breast cancer (BC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.26_suppl.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
112 Background: BC survivors are at higher risk of developing SNBM due to treatment effects and shared behavioral and genetic factors. Associations between histologic subtypes of primary BC and secondary endometrial or ovarian cancer have been reported. Less is known about subtype-specific associations with other secondary solid tumors. We aimed to determine the prevalence of SNBM across US Oncology practices and what subtype-specific associations, if any, exist between primary BC and SNBM. Methods: We conducted a retrospective database analysis identifying BC patients (pts) diagnosed between 01/2007 and 05/2013. SNBM were ascertained from codified fields in pts electronic records. Age at BC diagnosis, BC stage, estrogen receptor (ER), progesterone receptor (PR), HER2 status, BMI and smoking history were collected. Chi-square tests were used to compare categorical variables. Logistic regression was used to predict likelihood of secondary malignancies in separate multivariate models. Results: 105,795 pts with stage 0-IV BC were identified. 2,237 (2.1%) were diagnosed with ≥ 1 SNBM. Mean age at diagnosis and follow-up were 59.5 and 2.6 years respectively. Pts with SNBM were more likely to have: older age, ≥ stage I, HER-2 negative disease, BMI ≥25 and past/current smoking history. SNBM were most commonly: Non-small cell lung cancer (NSCLC) (n=346), colorectal (CRC) (n=250), uterine (n=192), ovarian (n=130), thyroid (n=106) and kidney cancer (n=73). No associations were found between BC subtypes and ovarian, uterine, thyroid or NSCLC. Significant positive and negative associations between triple-negative breast cancer (TNBC) and secondary CRC and kidney cancer, respectively, were noted. In multivariate analysis, TNBC was predictive of secondary kidney cancer (OR 2.00, p=0.019). TNBC (OR 0.47, p=0.009), age ≤55 (OR 0.27, p<0.0001) and BMI ≤30 (OR 0.64 for BMI 25-30, p=0.019) were negative predictors of secondary CRC. Conclusions: Our study is the first to report direct and inverse associations between primary TNBC and secondary kidney and CRC, respectively. The short follow-up precludes treatment-related effects. Results may potentially be attributed to genetic, environmental or lifestyle factors and warrant further research.
Collapse
Affiliation(s)
| | | | - Robyn K. Harrell
- US Oncology Network/McKesson Specialty Health, The Woodlands, TX
| | | | | | | |
Collapse
|